Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,2533895,terminal plasma half-life,"Ondansetron had a terminal plasma half-life of 3.0-3.5 h and plasma clearance (principally metabolic) of the order of 600 ml/min, and there was no evidence of accumulation at steady state.",The clinical pharmacology of ondansetron. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2533895/),h,3.0-3.5,22899,DB00904,Ondansetron
,2533895,plasma clearance,"Ondansetron had a terminal plasma half-life of 3.0-3.5 h and plasma clearance (principally metabolic) of the order of 600 ml/min, and there was no evidence of accumulation at steady state.",The clinical pharmacology of ondansetron. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2533895/),[ml] / [min],600,22900,DB00904,Ondansetron
,2533895,absolute oral bioavailability,The absolute oral bioavailability of ondansetron was 59%.,The clinical pharmacology of ondansetron. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2533895/),%,59,22901,DB00904,Ondansetron
,12296413,time to reach the maximal concentration (Tmax,"The time to reach the maximal concentration (Tmax, hour), the peak concentration (Cmax, ng/ ml) and the area under the concentration-time curve (AUC(0-infinity), ng x h/ml) of ondansetron for reference and test preparations were 2.6 + 1.8 vs 2.2 + 0.6, 49.5 +/- 18.9 vs 48.5 +/- 13.7 and 352.2 +/- 184.7 vs 323.8 +/- 154.5, respectively.",Bioequivalence study of ondansetron tablet in healthy Thai male volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12296413/),[h·ng] / [ml],2.6,23487,DB00904,Ondansetron
,12296413,peak concentration (Cmax,"The time to reach the maximal concentration (Tmax, hour), the peak concentration (Cmax, ng/ ml) and the area under the concentration-time curve (AUC(0-infinity), ng x h/ml) of ondansetron for reference and test preparations were 2.6 + 1.8 vs 2.2 + 0.6, 49.5 +/- 18.9 vs 48.5 +/- 13.7 and 352.2 +/- 184.7 vs 323.8 +/- 154.5, respectively.",Bioequivalence study of ondansetron tablet in healthy Thai male volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12296413/),[h·ng] / [ml],49.5,23488,DB00904,Ondansetron
,12296413,peak concentration (Cmax,"The time to reach the maximal concentration (Tmax, hour), the peak concentration (Cmax, ng/ ml) and the area under the concentration-time curve (AUC(0-infinity), ng x h/ml) of ondansetron for reference and test preparations were 2.6 + 1.8 vs 2.2 + 0.6, 49.5 +/- 18.9 vs 48.5 +/- 13.7 and 352.2 +/- 184.7 vs 323.8 +/- 154.5, respectively.",Bioequivalence study of ondansetron tablet in healthy Thai male volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12296413/),[h·ng] / [ml],48.5,23489,DB00904,Ondansetron
,12296413,area under the concentration-time curve (AUC(0-infinity),"The time to reach the maximal concentration (Tmax, hour), the peak concentration (Cmax, ng/ ml) and the area under the concentration-time curve (AUC(0-infinity), ng x h/ml) of ondansetron for reference and test preparations were 2.6 + 1.8 vs 2.2 + 0.6, 49.5 +/- 18.9 vs 48.5 +/- 13.7 and 352.2 +/- 184.7 vs 323.8 +/- 154.5, respectively.",Bioequivalence study of ondansetron tablet in healthy Thai male volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12296413/),[h·ng] / [ml],49.5,23490,DB00904,Ondansetron
,12296413,area under the concentration-time curve (AUC(0-infinity),"The time to reach the maximal concentration (Tmax, hour), the peak concentration (Cmax, ng/ ml) and the area under the concentration-time curve (AUC(0-infinity), ng x h/ml) of ondansetron for reference and test preparations were 2.6 + 1.8 vs 2.2 + 0.6, 49.5 +/- 18.9 vs 48.5 +/- 13.7 and 352.2 +/- 184.7 vs 323.8 +/- 154.5, respectively.",Bioequivalence study of ondansetron tablet in healthy Thai male volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12296413/),[h·ng] / [ml],48.5,23491,DB00904,Ondansetron
,12296413,area under the concentration-time curve (AUC(0-infinity),"The time to reach the maximal concentration (Tmax, hour), the peak concentration (Cmax, ng/ ml) and the area under the concentration-time curve (AUC(0-infinity), ng x h/ml) of ondansetron for reference and test preparations were 2.6 + 1.8 vs 2.2 + 0.6, 49.5 +/- 18.9 vs 48.5 +/- 13.7 and 352.2 +/- 184.7 vs 323.8 +/- 154.5, respectively.",Bioequivalence study of ondansetron tablet in healthy Thai male volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12296413/),[h·ng] / [ml],352.2,23492,DB00904,Ondansetron
,12296413,area under the concentration-time curve (AUC(0-infinity),"The time to reach the maximal concentration (Tmax, hour), the peak concentration (Cmax, ng/ ml) and the area under the concentration-time curve (AUC(0-infinity), ng x h/ml) of ondansetron for reference and test preparations were 2.6 + 1.8 vs 2.2 + 0.6, 49.5 +/- 18.9 vs 48.5 +/- 13.7 and 352.2 +/- 184.7 vs 323.8 +/- 154.5, respectively.",Bioequivalence study of ondansetron tablet in healthy Thai male volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12296413/),[h·ng] / [ml],323.8,23493,DB00904,Ondansetron
,17051369,plasma AUC ratios,"The mean plasma concentration profile of vinorelbine administered with aprepitant was identical to that following vinorelbine administered alone, with geometric mean vinorelbine plasma AUC ratios of treatment B day 1/treatment A day 1 and of treatment B day 8/treatment A day of 1.01 (0.93, 1.10) and 1.00 (0.92, 1.08), respectively.",Aprepitant when added to a standard antiemetic regimen consisting of ondansetron and dexamethasone does not affect vinorelbine pharmacokinetics in cancer patients. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17051369/),,1.01,25530,DB00904,Ondansetron
,17051369,plasma AUC ratios,"The mean plasma concentration profile of vinorelbine administered with aprepitant was identical to that following vinorelbine administered alone, with geometric mean vinorelbine plasma AUC ratios of treatment B day 1/treatment A day 1 and of treatment B day 8/treatment A day of 1.01 (0.93, 1.10) and 1.00 (0.92, 1.08), respectively.",Aprepitant when added to a standard antiemetic regimen consisting of ondansetron and dexamethasone does not affect vinorelbine pharmacokinetics in cancer patients. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17051369/),,1.00,25531,DB00904,Ondansetron
,22689921,flow rate,"The mobile phase, which consisted of a mixture of methanol and 20 mM ammonium formate (pH 5.00 ± 0.05; 75:25 v/v), was injected at a flow rate of 0.40 mL/min.",A rapid and highly sensitive UPLC-MS-MS method for the quantification of zolpidem tartrate in human EDTA plasma and its application to pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22689921/),[ml] / [min],0.40,27139,DB00904,Ondansetron
,22689921,retention times,The retention times of zolpidem and IS were approximately 1.76 and 1.22.,A rapid and highly sensitive UPLC-MS-MS method for the quantification of zolpidem tartrate in human EDTA plasma and its application to pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22689921/),,1.76,27140,DB00904,Ondansetron
,22689921,retention times,The retention times of zolpidem and IS were approximately 1.76 and 1.22.,A rapid and highly sensitive UPLC-MS-MS method for the quantification of zolpidem tartrate in human EDTA plasma and its application to pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22689921/),,1.22,27141,DB00904,Ondansetron
,22689921,run time,The LC run time was 3 min.,A rapid and highly sensitive UPLC-MS-MS method for the quantification of zolpidem tartrate in human EDTA plasma and its application to pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22689921/),min,3,27142,DB00904,Ondansetron
>,22689921,signal-to-noise (S/N),The lower detection limit [(signal-to-noise (S/N) > 3] was 0.04 ng/mL and the lower limit of quantification (S/N > 10) was 0.10 ng/mL.,A rapid and highly sensitive UPLC-MS-MS method for the quantification of zolpidem tartrate in human EDTA plasma and its application to pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22689921/),,3,27143,DB00904,Ondansetron
,22689921,signal-to-noise (S/N),The lower detection limit [(signal-to-noise (S/N) > 3] was 0.04 ng/mL and the lower limit of quantification (S/N > 10) was 0.10 ng/mL.,A rapid and highly sensitive UPLC-MS-MS method for the quantification of zolpidem tartrate in human EDTA plasma and its application to pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22689921/),[ng] / [ml],0.04,27144,DB00904,Ondansetron
>,22689921,S/N,The lower detection limit [(signal-to-noise (S/N) > 3] was 0.04 ng/mL and the lower limit of quantification (S/N > 10) was 0.10 ng/mL.,A rapid and highly sensitive UPLC-MS-MS method for the quantification of zolpidem tartrate in human EDTA plasma and its application to pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22689921/),,10,27145,DB00904,Ondansetron
,22689921,S/N,The lower detection limit [(signal-to-noise (S/N) > 3] was 0.04 ng/mL and the lower limit of quantification (S/N > 10) was 0.10 ng/mL.,A rapid and highly sensitive UPLC-MS-MS method for the quantification of zolpidem tartrate in human EDTA plasma and its application to pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22689921/),[ng] / [ml],0.10,27146,DB00904,Ondansetron
,22689921,Recovery,Recovery of zolpidem in human plasma was 87.00% and IS recovery was 81.60%.,A rapid and highly sensitive UPLC-MS-MS method for the quantification of zolpidem tartrate in human EDTA plasma and its application to pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22689921/),%,87.00,27147,DB00904,Ondansetron
,22689921,recovery,Recovery of zolpidem in human plasma was 87.00% and IS recovery was 81.60%.,A rapid and highly sensitive UPLC-MS-MS method for the quantification of zolpidem tartrate in human EDTA plasma and its application to pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22689921/),%,81.60,27148,DB00904,Ondansetron
,22689921,T(max),"The primary pharmacokinetic parameters were T(max) (h) = (1.25 ± 0.725), C(max) (ng/mL) (127.80 ± 34.081), AUC(0→t), = (665.37 ± 320.982) and AUC(0→∞), 686.03 ± 342.952, respectively.",A rapid and highly sensitive UPLC-MS-MS method for the quantification of zolpidem tartrate in human EDTA plasma and its application to pharmacokinetic study. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22689921/),h,1.25,27149,DB00904,Ondansetron
,22689921,C(max),"The primary pharmacokinetic parameters were T(max) (h) = (1.25 ± 0.725), C(max) (ng/mL) (127.80 ± 34.081), AUC(0→t), = (665.37 ± 320.982) and AUC(0→∞), 686.03 ± 342.952, respectively.",A rapid and highly sensitive UPLC-MS-MS method for the quantification of zolpidem tartrate in human EDTA plasma and its application to pharmacokinetic study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22689921/),[ng] / [ml],127.80,27150,DB00904,Ondansetron
,22689921,AUC(0→t),"The primary pharmacokinetic parameters were T(max) (h) = (1.25 ± 0.725), C(max) (ng/mL) (127.80 ± 34.081), AUC(0→t), = (665.37 ± 320.982) and AUC(0→∞), 686.03 ± 342.952, respectively.",A rapid and highly sensitive UPLC-MS-MS method for the quantification of zolpidem tartrate in human EDTA plasma and its application to pharmacokinetic study. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22689921/),,665.37,27151,DB00904,Ondansetron
,22689921,AUC(0→∞),"The primary pharmacokinetic parameters were T(max) (h) = (1.25 ± 0.725), C(max) (ng/mL) (127.80 ± 34.081), AUC(0→t), = (665.37 ± 320.982) and AUC(0→∞), 686.03 ± 342.952, respectively.",A rapid and highly sensitive UPLC-MS-MS method for the quantification of zolpidem tartrate in human EDTA plasma and its application to pharmacokinetic study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22689921/),,686.03,27152,DB00904,Ondansetron
,16317728,MTD,The MTD of irofulven administered daily x 5 every 28 days with concomitant ondansetron and dexamethasone is 6 mg/m(2)/day in heavily pre-treated patients and 10 mg/m(2)/day in less heavily pre-treated patients.,Phase I trial of irofulven (MGI 114) in pediatric patients with solid tumors. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16317728/),[mg] / [d·m(2)],6,37512,DB00904,Ondansetron
,16317728,MTD,The MTD of irofulven administered daily x 5 every 28 days with concomitant ondansetron and dexamethasone is 6 mg/m(2)/day in heavily pre-treated patients and 10 mg/m(2)/day in less heavily pre-treated patients.,Phase I trial of irofulven (MGI 114) in pediatric patients with solid tumors. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16317728/),[mg] / [d·m(2)],10,37513,DB00904,Ondansetron
,26667224,AUC,"Mean AUC (ng/mL·h) of subcutaneous ondansetron was 301.4 (geriatric), 415.2 (CKD), and 587.0 (liver).","Limited sampling pharmacokinetics of subcutaneous ondansetron in healthy geriatric cats, cats with chronic kidney disease, and cats with liver disease. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26667224/),[ng] / [h·ml],301.4,44551,DB00904,Ondansetron
,26667224,AUC,"Mean AUC (ng/mL·h) of subcutaneous ondansetron was 301.4 (geriatric), 415.2 (CKD), and 587.0 (liver).","Limited sampling pharmacokinetics of subcutaneous ondansetron in healthy geriatric cats, cats with chronic kidney disease, and cats with liver disease. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26667224/),[ng] / [h·ml],415.2,44552,DB00904,Ondansetron
,26667224,AUC,"Mean AUC (ng/mL·h) of subcutaneous ondansetron was 301.4 (geriatric), 415.2 (CKD), and 587.0 (liver).","Limited sampling pharmacokinetics of subcutaneous ondansetron in healthy geriatric cats, cats with chronic kidney disease, and cats with liver disease. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26667224/),[ng] / [h·ml],587.0,44553,DB00904,Ondansetron
,26667224,CL/F,"CL/F (L/h/kg) of SQ ondansetron was 1.157 (geriatric), 0.967 (CKD), and 0.795 (liver).","Limited sampling pharmacokinetics of subcutaneous ondansetron in healthy geriatric cats, cats with chronic kidney disease, and cats with liver disease. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26667224/),[l] / [h·kg],1.157,44554,DB00904,Ondansetron
,26667224,CL/F,"CL/F (L/h/kg) of SQ ondansetron was 1.157 (geriatric), 0.967 (CKD), and 0.795 (liver).","Limited sampling pharmacokinetics of subcutaneous ondansetron in healthy geriatric cats, cats with chronic kidney disease, and cats with liver disease. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26667224/),[l] / [h·kg],0.967,44555,DB00904,Ondansetron
,26667224,CL/F,"CL/F (L/h/kg) of SQ ondansetron was 1.157 (geriatric), 0.967 (CKD), and 0.795 (liver).","Limited sampling pharmacokinetics of subcutaneous ondansetron in healthy geriatric cats, cats with chronic kidney disease, and cats with liver disease. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26667224/),[l] / [h·kg],0.795,44556,DB00904,Ondansetron
,10584976,elimination half-life,"Following i.v. ondansetron, the mean values of its elimination half-life, its plasma clearance, and its volume of distribution were 4.5 hours, 398 ml/min, and 130 liters, respectively.",Pharmacokinetics and bioequivalence testing of generic ondansetron preparations in healthy Thai male volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10584976/),h,4.5,45462,DB00904,Ondansetron
,10584976,plasma clearance,"Following i.v. ondansetron, the mean values of its elimination half-life, its plasma clearance, and its volume of distribution were 4.5 hours, 398 ml/min, and 130 liters, respectively.",Pharmacokinetics and bioequivalence testing of generic ondansetron preparations in healthy Thai male volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10584976/),[ml] / [min],398,45463,DB00904,Ondansetron
,10584976,volume of distribution,"Following i.v. ondansetron, the mean values of its elimination half-life, its plasma clearance, and its volume of distribution were 4.5 hours, 398 ml/min, and 130 liters, respectively.",Pharmacokinetics and bioequivalence testing of generic ondansetron preparations in healthy Thai male volunteers. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10584976/),l,130,45464,DB00904,Ondansetron
,10584976,oral bioavailability,"Its oral bioavailability averaged 67%, and the elimination half-life after oral administration was 5.6 hours.",Pharmacokinetics and bioequivalence testing of generic ondansetron preparations in healthy Thai male volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10584976/),%,67,45465,DB00904,Ondansetron
,10584976,elimination half-life,"Its oral bioavailability averaged 67%, and the elimination half-life after oral administration was 5.6 hours.",Pharmacokinetics and bioequivalence testing of generic ondansetron preparations in healthy Thai male volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10584976/),h,5.6,45466,DB00904,Ondansetron
,10584976,time to reach the maximal concentration (Tmax,"The time to reach the maximal concentration (Tmax, hour) of Zofran (1.21 +/- 0.26) was statistically faster than that of Vomitron 8 (1.33 +/- 0.54) and Vomitron 4 (1.46 +/- 0.50).",Pharmacokinetics and bioequivalence testing of generic ondansetron preparations in healthy Thai male volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10584976/),h,1.21,45467,DB00904,Ondansetron
,10584976,time to reach the maximal concentration (Tmax,"The time to reach the maximal concentration (Tmax, hour) of Zofran (1.21 +/- 0.26) was statistically faster than that of Vomitron 8 (1.33 +/- 0.54) and Vomitron 4 (1.46 +/- 0.50).",Pharmacokinetics and bioequivalence testing of generic ondansetron preparations in healthy Thai male volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10584976/),h,1.33,45468,DB00904,Ondansetron
,10584976,time to reach the maximal concentration (Tmax,"The time to reach the maximal concentration (Tmax, hour) of Zofran (1.21 +/- 0.26) was statistically faster than that of Vomitron 8 (1.33 +/- 0.54) and Vomitron 4 (1.46 +/- 0.50).",Pharmacokinetics and bioequivalence testing of generic ondansetron preparations in healthy Thai male volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10584976/),h,1.46,45469,DB00904,Ondansetron
,18985740,Complete response (CR) rates,Complete response (CR) rates were 35.7% for aprepitant triple therapy versus 5.6% for the control group.,"Aprepitant in adolescent patients for prevention of chemotherapy-induced nausea and vomiting: a randomized, double-blind, placebo-controlled study of efficacy and tolerability. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18985740/),%,35.7,50239,DB00904,Ondansetron
,18985740,Complete response (CR) rates,Complete response (CR) rates were 35.7% for aprepitant triple therapy versus 5.6% for the control group.,"Aprepitant in adolescent patients for prevention of chemotherapy-induced nausea and vomiting: a randomized, double-blind, placebo-controlled study of efficacy and tolerability. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18985740/),%,5.6,50240,DB00904,Ondansetron
,28814338,nausea behaviour score,The onset of nausea-like behaviour in the placebo-treated group occurred at t3.5h and peaked at t4.75h with nausea behaviour score of 58.5 ± 4.6 mm.,"Anti-nausea effects and pharmacokinetics of ondansetron, maropitant and metoclopramide in a low-dose cisplatin model of nausea and vomiting in the dog: a blinded crossover study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28814338/),,58.5,57067,DB00904,Ondansetron
,28814338,terminal half-lives,"The terminal half-lives (harmonic mean ± pseudo SD) for ondansetron, maropitant and metoclopramide were 1.21 ± 0.51, 5.62 ± 0.77 and 0.87 ± 0.17 h respectively.","Anti-nausea effects and pharmacokinetics of ondansetron, maropitant and metoclopramide in a low-dose cisplatin model of nausea and vomiting in the dog: a blinded crossover study. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/28814338/),h,1.21,57068,DB00904,Ondansetron
,28814338,terminal half-lives,"The terminal half-lives (harmonic mean ± pseudo SD) for ondansetron, maropitant and metoclopramide were 1.21 ± 0.51, 5.62 ± 0.77 and 0.87 ± 0.17 h respectively.","Anti-nausea effects and pharmacokinetics of ondansetron, maropitant and metoclopramide in a low-dose cisplatin model of nausea and vomiting in the dog: a blinded crossover study. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/28814338/),h,5.62,57069,DB00904,Ondansetron
,28814338,terminal half-lives,"The terminal half-lives (harmonic mean ± pseudo SD) for ondansetron, maropitant and metoclopramide were 1.21 ± 0.51, 5.62 ± 0.77 and 0.87 ± 0.17 h respectively.","Anti-nausea effects and pharmacokinetics of ondansetron, maropitant and metoclopramide in a low-dose cisplatin model of nausea and vomiting in the dog: a blinded crossover study. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/28814338/),h,0.87,57070,DB00904,Ondansetron
,8690814,absolute bioavailability,"After a single, oral dose of ondansetron, mean absolute bioavailability increased markedly with increased hepatic insufficiency (approaching 100% in the group with severe hepatic impairment versus 66% for control subjects).",Pharmacokinetics of ondansetron in patients with hepatic insufficiency. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8690814/),%,100,64283,DB00904,Ondansetron
,8690814,absolute bioavailability,"After a single, oral dose of ondansetron, mean absolute bioavailability increased markedly with increased hepatic insufficiency (approaching 100% in the group with severe hepatic impairment versus 66% for control subjects).",Pharmacokinetics of ondansetron in patients with hepatic insufficiency. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8690814/),%,66,64284,DB00904,Ondansetron
,10511774,oral bioavailability,The oral bioavailability of ondansetron averaged 67 per cent and the elimination half-life after oral administration was 5.6 hours.,"Pharmacokinetics and bioavailability studies of generic ondansetron, and the innovator preparation, in healthy Thai male volunteers. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10511774/),%,67,66657,DB00904,Ondansetron
,10511774,elimination half-life,The oral bioavailability of ondansetron averaged 67 per cent and the elimination half-life after oral administration was 5.6 hours.,"Pharmacokinetics and bioavailability studies of generic ondansetron, and the innovator preparation, in healthy Thai male volunteers. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10511774/),h,5.6,66658,DB00904,Ondansetron
,32017606,half-life,"Following administration of all three doses, measured ondansetron plasma levels (≈30-3000 pg/mL) were below levels achieved with doses usually administered in the clinic, with a rapid absorption phase and a short half-life (≈30-40 min).",Pharmacokinetic profile of the selective 5-HT3 receptor antagonist ondansetron in the rat: an original study and a minireview of the behavioural pharmacological literature in the rat. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32017606/),min,30-40,69704,DB00904,Ondansetron
,32017606,brain to plasma ratios,"We also found that brain levels of ondansetron at 1 μg/kg were significantly lower than plasma levels, with brain to plasma ratios of 0.45 and 0.46 in the motor and pre-frontal cortices.",Pharmacokinetic profile of the selective 5-HT3 receptor antagonist ondansetron in the rat: an original study and a minireview of the behavioural pharmacological literature in the rat. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32017606/),,0,69705,DB00904,Ondansetron
,20490798,clearance,"The population means for clearance and central volume of distribution were 2.05 l/h/70 kg and 9.21 l/70 kg with the corresponding between-subject variabilities, 0.26 and 0.28.",Developmental pharmacokinetics of etoposide in 67 children: lack of dexamethasone effect. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20490798/),[l] / [70·h·kg],2.05,73511,DB00904,Ondansetron
,20490798,central volume of distribution,"The population means for clearance and central volume of distribution were 2.05 l/h/70 kg and 9.21 l/70 kg with the corresponding between-subject variabilities, 0.26 and 0.28.",Developmental pharmacokinetics of etoposide in 67 children: lack of dexamethasone effect. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20490798/),[l] / [70·kg],9.21,73512,DB00904,Ondansetron
,19577876,flow rate,"The mobile phase was a mixture of acetonitrile and 0.5% formic acid solution (30:70, v/v) at a flow rate of 0.2 mL min(-1).",Determination of dexmedetomidine in human plasma using high performance liquid chromatography coupled with tandem mass spectrometric detection: application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19577876/),[ml] / [min],0.2,75123,DB00904,Ondansetron
,19577876,m,The detection was performed on a triple quadrupole tandem mass spectrometer in the selected reaction monitoring (SRM) mode using the respective [M+H]+ ions m/z 201.0-->95.1 for DMED and m/z 294.1-->170.1 for the IS.,Determination of dexmedetomidine in human plasma using high performance liquid chromatography coupled with tandem mass spectrometric detection: application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19577876/),,201.0,75124,DB00904,Ondansetron
,19577876,m/,The detection was performed on a triple quadrupole tandem mass spectrometer in the selected reaction monitoring (SRM) mode using the respective [M+H]+ ions m/z 201.0-->95.1 for DMED and m/z 294.1-->170.1 for the IS.,Determination of dexmedetomidine in human plasma using high performance liquid chromatography coupled with tandem mass spectrometric detection: application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19577876/),,294.1,75125,DB00904,Ondansetron
,8488393,absolute bioavailability,"Plasma concentrations of ondansetron peak 1 hour after an oral dose, and the tablet has an absolute bioavailability of 59%.",Ondansetron: a novel antiemetic agent. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8488393/),%,59,89028,DB00904,Ondansetron
,8488393,half-life,"The half-life of ondansetron is 3.5 hours in healthy volunteers; elderly patients have a slightly reduced clearance, and pediatric patients have increased clearance.",Ondansetron: a novel antiemetic agent. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8488393/),h,3.5,89029,DB00904,Ondansetron
,7586904,bioavailability,"Owing to hepatic first-pass metabolism, its bioavailability is only about 60% compared with ondansetron administered by infusion over 15 minutes.",Ondansetron clinical pharmacokinetics. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7586904/),%,60,91176,DB00904,Ondansetron
,7586904,time to reach peak concentration,"Since the time to reach peak concentration is 0.5 to 2 hours after oral ingestion, the drug should be administered at least 30 minutes before chemotherapy.",Ondansetron clinical pharmacokinetics. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7586904/),h,0.5 to 2,91177,DB00904,Ondansetron
,7586904,volume of distribution,Ondansetron is widely distributed (volume of distribution approximately 160L) and binds moderately (70 to 76%) to plasma proteins; the elimination half-life averages approximately 3.8 +/- 1 hours.,Ondansetron clinical pharmacokinetics. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7586904/),l,160,91178,DB00904,Ondansetron
,7586904,elimination half-life,Ondansetron is widely distributed (volume of distribution approximately 160L) and binds moderately (70 to 76%) to plasma proteins; the elimination half-life averages approximately 3.8 +/- 1 hours.,Ondansetron clinical pharmacokinetics. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7586904/),h,3.8,91179,DB00904,Ondansetron
,19798490,half-life,A maturation process with a half-life of approximately 4 months was incorporated to describe a decrease in clearance (CL) in infants.,Population pharmacokinetics of intravenous ondansetron in oncology and surgical patients aged 1-48 months. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19798490/),month,4,97711,DB00904,Ondansetron
,19798490,Clearance,Clearance [95% confidence interval (CI)] for a typical patient was 1.53 (1.34-1.78) L/h/kg(0.75) with an interindividual variability of 56.8%.,Population pharmacokinetics of intravenous ondansetron in oncology and surgical patients aged 1-48 months. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19798490/),[l] / [h·kg],1.53,97712,DB00904,Ondansetron
,17679558,run time,This method involves a rapid assay for the determination of granisetron in a small volume of plasma with a run time of 12 min using ondansetron as an internal standard.,Nasal absorption studies of granisetron in rats using a validated high-performance liquid chromatographic method with mass spectrometric detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17679558/),min,12,105037,DB00904,Ondansetron
,17679558,m/z,"Granisetron and ondansetron were detected at m/z values of 313.2 and 294.2, respectively.",Nasal absorption studies of granisetron in rats using a validated high-performance liquid chromatographic method with mass spectrometric detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17679558/),,313.2,105038,DB00904,Ondansetron
,17679558,m/z,"Granisetron and ondansetron were detected at m/z values of 313.2 and 294.2, respectively.",Nasal absorption studies of granisetron in rats using a validated high-performance liquid chromatographic method with mass spectrometric detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17679558/),,294.2,105039,DB00904,Ondansetron
,31937128,bioavailability,"In elderly subjects, bioavailability may be somewhat higher (65%) and lower clearance, presumably due to reduced hepatic first-pass metabolism.",Sustained release formulation of Ondansetron HCl using osmotic drug delivery approach. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31937128/),%,65,106156,DB00904,Ondansetron
,31937128,terminal elimination half-life,OSH is extensively distributed in the body; about 70-75% of the drug in plasma is protein-bound and terminal elimination half-life is about 3 h after oral administration.,Sustained release formulation of Ondansetron HCl using osmotic drug delivery approach. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/31937128/),h,3,106157,DB00904,Ondansetron
>,27336702,m/z,"Quantitation was carried out using the positive ionization mode with multiple reaction monitoring (MRM) at m/z 394.20>278.04 (ERL), m/z 372.25>72.01 (TAM), and m/z 294.18>170.16 (OND).",Simultaneous determination of erlotinib and tamoxifen in rat plasma using UPLC-MS/MS: Application to pharmacokinetic interaction studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27336702/),,39,107053,DB00904,Ondansetron
>,27336702,m/z,"Quantitation was carried out using the positive ionization mode with multiple reaction monitoring (MRM) at m/z 394.20>278.04 (ERL), m/z 372.25>72.01 (TAM), and m/z 294.18>170.16 (OND).",Simultaneous determination of erlotinib and tamoxifen in rat plasma using UPLC-MS/MS: Application to pharmacokinetic interaction studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27336702/),,278.04,107054,DB00904,Ondansetron
>,27336702,m/z,"Quantitation was carried out using the positive ionization mode with multiple reaction monitoring (MRM) at m/z 394.20>278.04 (ERL), m/z 372.25>72.01 (TAM), and m/z 294.18>170.16 (OND).",Simultaneous determination of erlotinib and tamoxifen in rat plasma using UPLC-MS/MS: Application to pharmacokinetic interaction studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27336702/),,372.25,107055,DB00904,Ondansetron
>,27336702,m/z,"Quantitation was carried out using the positive ionization mode with multiple reaction monitoring (MRM) at m/z 394.20>278.04 (ERL), m/z 372.25>72.01 (TAM), and m/z 294.18>170.16 (OND).",Simultaneous determination of erlotinib and tamoxifen in rat plasma using UPLC-MS/MS: Application to pharmacokinetic interaction studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27336702/),,72.01,107056,DB00904,Ondansetron
>,27336702,m/z,"Quantitation was carried out using the positive ionization mode with multiple reaction monitoring (MRM) at m/z 394.20>278.04 (ERL), m/z 372.25>72.01 (TAM), and m/z 294.18>170.16 (OND).",Simultaneous determination of erlotinib and tamoxifen in rat plasma using UPLC-MS/MS: Application to pharmacokinetic interaction studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27336702/),,294.18,107057,DB00904,Ondansetron
>,27336702,m/z,"Quantitation was carried out using the positive ionization mode with multiple reaction monitoring (MRM) at m/z 394.20>278.04 (ERL), m/z 372.25>72.01 (TAM), and m/z 294.18>170.16 (OND).",Simultaneous determination of erlotinib and tamoxifen in rat plasma using UPLC-MS/MS: Application to pharmacokinetic interaction studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27336702/),,170.16,107058,DB00904,Ondansetron
,21822913,area under curve (0-∞),"The average area under curve (0-∞) of casopitant after a single 90-mg IV dose was 8,390 ng h/mL.","Single-dose intravenous casopitant in combination with ondansetron and dexamethasone for the prevention of oxaliplatin-induced nausea and vomiting: a multicenter, randomized, double-blind, active-controlled, two arm, parallel group study. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21822913/),[h·ng] / [ml],"8,390",109312,DB00904,Ondansetron
,8140047,Absolute bioavailability,"Absolute bioavailability after the oral dosing, colonic infusion, and rectal administration averaged 71 +/- 14, 74 +/- 26, and 58 +/- 18%, respectively.","Comparison of the pharmacokinetics of an ondansetron solution (8 mg) when administered intravenously, orally, to the colon, and to the rectum. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8140047/),%,71,111019,DB00904,Ondansetron
,8140047,Absolute bioavailability,"Absolute bioavailability after the oral dosing, colonic infusion, and rectal administration averaged 71 +/- 14, 74 +/- 26, and 58 +/- 18%, respectively.","Comparison of the pharmacokinetics of an ondansetron solution (8 mg) when administered intravenously, orally, to the colon, and to the rectum. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8140047/),%,74,111020,DB00904,Ondansetron
,8140047,Absolute bioavailability,"Absolute bioavailability after the oral dosing, colonic infusion, and rectal administration averaged 71 +/- 14, 74 +/- 26, and 58 +/- 18%, respectively.","Comparison of the pharmacokinetics of an ondansetron solution (8 mg) when administered intravenously, orally, to the colon, and to the rectum. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8140047/),%,58,111021,DB00904,Ondansetron
,8140047,absorption half-lives,"Mean absorption half-lives were 0.66, 1.1, and 0.75 hr after the oral, colonic, and rectal administrations, respectively.","Comparison of the pharmacokinetics of an ondansetron solution (8 mg) when administered intravenously, orally, to the colon, and to the rectum. ","t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8140047/),h,0.66,111022,DB00904,Ondansetron
,8140047,absorption half-lives,"Mean absorption half-lives were 0.66, 1.1, and 0.75 hr after the oral, colonic, and rectal administrations, respectively.","Comparison of the pharmacokinetics of an ondansetron solution (8 mg) when administered intravenously, orally, to the colon, and to the rectum. ","t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8140047/),h,1.1,111023,DB00904,Ondansetron
,8140047,absorption half-lives,"Mean absorption half-lives were 0.66, 1.1, and 0.75 hr after the oral, colonic, and rectal administrations, respectively.","Comparison of the pharmacokinetics of an ondansetron solution (8 mg) when administered intravenously, orally, to the colon, and to the rectum. ","t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8140047/),h,0.75,111024,DB00904,Ondansetron
,18978345,maximum dose,"For this phase I study, a starting dose of 0.5 mg of periocular topotecan administered through a 25-gauge needle was given with intrapatient escalation at a rate of 0.5 mg/cycle according to toxicity, up to a maximum dose of 2 mg.",A phase I study of periocular topotecan in children with intraocular retinoblastoma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18978345/),,2,111084,DB00904,Ondansetron
,8688345,area under the plasma concentration curve (AUC),"The median area under the plasma concentration curve (AUC) obtained with the oral formulation was 226 ng ml-1h-1 (range 91-750), and the median maximum plasma level (Cmax) was 50.5 ng ml-1 (range 24.7-199.6) after a dose of 8 mg.",Pharmacokinetic profile and clinical efficacy of a once-daily ondansetron suppository in cyclophosphamide-induced emesis: a double blind comparative study with ondansetron tablets. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8688345/),[ng] / [ml],226,112073,DB00904,Ondansetron
,8688345,maximum plasma level (Cmax),"The median area under the plasma concentration curve (AUC) obtained with the oral formulation was 226 ng ml-1h-1 (range 91-750), and the median maximum plasma level (Cmax) was 50.5 ng ml-1 (range 24.7-199.6) after a dose of 8 mg.",Pharmacokinetic profile and clinical efficacy of a once-daily ondansetron suppository in cyclophosphamide-induced emesis: a double blind comparative study with ondansetron tablets. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8688345/),[ng] / [ml],50.5,112074,DB00904,Ondansetron
,8688345,AUC,For the ondansetron suppository the median AUC was 140 ng ml-1h-1 range (77-405) and the median Cmax was 17.1 ng ml-1 (range 13-48.3) after a dose of 16 mg.,Pharmacokinetic profile and clinical efficacy of a once-daily ondansetron suppository in cyclophosphamide-induced emesis: a double blind comparative study with ondansetron tablets. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8688345/),[ng] / [ml],140,112075,DB00904,Ondansetron
,8688345,Cmax,For the ondansetron suppository the median AUC was 140 ng ml-1h-1 range (77-405) and the median Cmax was 17.1 ng ml-1 (range 13-48.3) after a dose of 16 mg.,Pharmacokinetic profile and clinical efficacy of a once-daily ondansetron suppository in cyclophosphamide-induced emesis: a double blind comparative study with ondansetron tablets. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8688345/),[ng] / [ml],17.1,112076,DB00904,Ondansetron
,8688345,time to reach the maximum level (Tmax),The median time to reach the maximum level (Tmax) was 60 min (range 28-120) with the oral formulation and 209 min (range 90-420) with the suppository.,Pharmacokinetic profile and clinical efficacy of a once-daily ondansetron suppository in cyclophosphamide-induced emesis: a double blind comparative study with ondansetron tablets. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8688345/),min,60,112077,DB00904,Ondansetron
,8688345,time to reach the maximum level (Tmax),The median time to reach the maximum level (Tmax) was 60 min (range 28-120) with the oral formulation and 209 min (range 90-420) with the suppository.,Pharmacokinetic profile and clinical efficacy of a once-daily ondansetron suppository in cyclophosphamide-induced emesis: a double blind comparative study with ondansetron tablets. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8688345/),min,209,112078,DB00904,Ondansetron
greater,9215605,bioavailable,"Experimental investigations show that orally it is rapidly absorbed (about 90 min), is highly bioavailable (greater than 90%), has a long half-life (about 12 h) and is more potent (about 10 times) in animal models than ondansetron, currently standard therapy for the prophylactic control of chemotherapy induced nausea and vomiting.","Comparison of oral itasetron with oral ondansetron: results of a double-blind, active-controlled phase II study in chemotherapy-naive patients receiving moderately emetogenic chemotherapy. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9215605/),%,90,112383,DB00904,Ondansetron
,9215605,half-life,"Experimental investigations show that orally it is rapidly absorbed (about 90 min), is highly bioavailable (greater than 90%), has a long half-life (about 12 h) and is more potent (about 10 times) in animal models than ondansetron, currently standard therapy for the prophylactic control of chemotherapy induced nausea and vomiting.","Comparison of oral itasetron with oral ondansetron: results of a double-blind, active-controlled phase II study in chemotherapy-naive patients receiving moderately emetogenic chemotherapy. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9215605/),h,12,112384,DB00904,Ondansetron
,24279581,entrapment efficiency,"Developed nasal microspheres possess entrapment efficiency of 80-89%, higher mucoadhesion of 72-84% across goat nasal mucosa.",Bioavailability enhancement of ondansetron after nasal administration of Caesalpinia pulcherrima-based microspheres. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24279581/),%,80-89,116231,DB00904,Ondansetron
,7554705,plasma clearance,"Mean plasma clearance was 0.50 L.hr-1.kg-1 and 0.39 L.hr-1.kg-1, the mean volume of distribution at steady-state was 1.70 L.kg-1 and 1.61 L.kg-1, and the mean plasma terminal half-life was 2.6 hours and 3.1 hours for the 2 mg and 4 mg groups, respectively.","Pharmacokinetics of intravenous ondansetron in healthy children undergoing ear, nose, and throat surgery. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7554705/),[l] / [h·kg],0.50,119326,DB00904,Ondansetron
,7554705,plasma clearance,"Mean plasma clearance was 0.50 L.hr-1.kg-1 and 0.39 L.hr-1.kg-1, the mean volume of distribution at steady-state was 1.70 L.kg-1 and 1.61 L.kg-1, and the mean plasma terminal half-life was 2.6 hours and 3.1 hours for the 2 mg and 4 mg groups, respectively.","Pharmacokinetics of intravenous ondansetron in healthy children undergoing ear, nose, and throat surgery. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7554705/),[l] / [h·kg],0.39,119327,DB00904,Ondansetron
,7554705,volume of distribution at steady-state,"Mean plasma clearance was 0.50 L.hr-1.kg-1 and 0.39 L.hr-1.kg-1, the mean volume of distribution at steady-state was 1.70 L.kg-1 and 1.61 L.kg-1, and the mean plasma terminal half-life was 2.6 hours and 3.1 hours for the 2 mg and 4 mg groups, respectively.","Pharmacokinetics of intravenous ondansetron in healthy children undergoing ear, nose, and throat surgery. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7554705/),[l] / [kg],1.70,119328,DB00904,Ondansetron
,7554705,volume of distribution at steady-state,"Mean plasma clearance was 0.50 L.hr-1.kg-1 and 0.39 L.hr-1.kg-1, the mean volume of distribution at steady-state was 1.70 L.kg-1 and 1.61 L.kg-1, and the mean plasma terminal half-life was 2.6 hours and 3.1 hours for the 2 mg and 4 mg groups, respectively.","Pharmacokinetics of intravenous ondansetron in healthy children undergoing ear, nose, and throat surgery. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7554705/),[l] / [kg],1.61,119329,DB00904,Ondansetron
,7554705,plasma terminal half-life,"Mean plasma clearance was 0.50 L.hr-1.kg-1 and 0.39 L.hr-1.kg-1, the mean volume of distribution at steady-state was 1.70 L.kg-1 and 1.61 L.kg-1, and the mean plasma terminal half-life was 2.6 hours and 3.1 hours for the 2 mg and 4 mg groups, respectively.","Pharmacokinetics of intravenous ondansetron in healthy children undergoing ear, nose, and throat surgery. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7554705/),h,2.6,119330,DB00904,Ondansetron
,7554705,plasma terminal half-life,"Mean plasma clearance was 0.50 L.hr-1.kg-1 and 0.39 L.hr-1.kg-1, the mean volume of distribution at steady-state was 1.70 L.kg-1 and 1.61 L.kg-1, and the mean plasma terminal half-life was 2.6 hours and 3.1 hours for the 2 mg and 4 mg groups, respectively.","Pharmacokinetics of intravenous ondansetron in healthy children undergoing ear, nose, and throat surgery. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7554705/),h,3.1,119331,DB00904,Ondansetron
,7554705,plasma clearance,"On a body surface area basis, mean plasma clearance was 14.0 and 13.7 L.hr-1.m-2 and mean volume of distribution was 47.7 and 55.9 L.m-2 for the 2 and 4 mg groups, respectively.","Pharmacokinetics of intravenous ondansetron in healthy children undergoing ear, nose, and throat surgery. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7554705/),[l] / [(m)^2·h],14.0,119332,DB00904,Ondansetron
,7554705,plasma clearance,"On a body surface area basis, mean plasma clearance was 14.0 and 13.7 L.hr-1.m-2 and mean volume of distribution was 47.7 and 55.9 L.m-2 for the 2 and 4 mg groups, respectively.","Pharmacokinetics of intravenous ondansetron in healthy children undergoing ear, nose, and throat surgery. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7554705/),[l] / [(m)^2·h],13.7,119333,DB00904,Ondansetron
,7554705,volume of distribution,"On a body surface area basis, mean plasma clearance was 14.0 and 13.7 L.hr-1.m-2 and mean volume of distribution was 47.7 and 55.9 L.m-2 for the 2 and 4 mg groups, respectively.","Pharmacokinetics of intravenous ondansetron in healthy children undergoing ear, nose, and throat surgery. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7554705/),[l] / [(m)^2],47.7,119334,DB00904,Ondansetron
,7554705,volume of distribution,"On a body surface area basis, mean plasma clearance was 14.0 and 13.7 L.hr-1.m-2 and mean volume of distribution was 47.7 and 55.9 L.m-2 for the 2 and 4 mg groups, respectively.","Pharmacokinetics of intravenous ondansetron in healthy children undergoing ear, nose, and throat surgery. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7554705/),[l] / [(m)^2],55.9,119335,DB00904,Ondansetron
,15616299,Systemic clearance,"Systemic clearance ranged from 0.2 to 0.3 liters/h/kg, and the tigecycline half-life ranged from 37 to 67 h.",Pharmacokinetics of tigecycline after single and multiple doses in healthy subjects. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15616299/),[l] / [h·kg],0.2 to 0.3,121812,DB00904,Ondansetron
,15616299,half-life,"Systemic clearance ranged from 0.2 to 0.3 liters/h/kg, and the tigecycline half-life ranged from 37 to 67 h.",Pharmacokinetics of tigecycline after single and multiple doses in healthy subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15616299/),h,37 to 67,121813,DB00904,Ondansetron
,15616299,volume of distribution,"Tigecycline had a large volume of distribution (7 to 10 liters/kg), indicating extensive distribution into the tissues.",Pharmacokinetics of tigecycline after single and multiple doses in healthy subjects. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15616299/),[l] / [kg],7 to 10,121814,DB00904,Ondansetron
,8261430,nadir,"At the recommended phase II dose (100 mg/m2/day x 5), the median WBC nadir following the first cycle was 2.5 x 10(3)/microliters (range, 0.6-7.6) occurring on day 36, and the median platelet nadir was 87 x 10(3)/microliters (range, 9-155) occurring on day 26.",Phase I and pharmacokinetic study of a new antineoplastic agent: pyrazine diazohydroxide (NSC 361456). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8261430/),,2.5 x,122605,DB00904,Ondansetron
,8261430,platelet nadir,"At the recommended phase II dose (100 mg/m2/day x 5), the median WBC nadir following the first cycle was 2.5 x 10(3)/microliters (range, 0.6-7.6) occurring on day 36, and the median platelet nadir was 87 x 10(3)/microliters (range, 9-155) occurring on day 26.",Phase I and pharmacokinetic study of a new antineoplastic agent: pyrazine diazohydroxide (NSC 361456). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8261430/),,87 x,122606,DB00904,Ondansetron
,8261430,alpha-half-life (t1/2 alpha),"Pharmacokinetic parameters for 12 patients analyzed by the 3-compartment model revealed an alpha-half-life (t1/2 alpha) of 2.83 +/- 1.57 (mean +/- SD), a t1/2 beta of 11.9 +/- 4.42, and a t1/2 gamma of 161 +/- 47.1 min, with a mean clearance of 1.86 +/- 0.91 liters/min.",Phase I and pharmacokinetic study of a new antineoplastic agent: pyrazine diazohydroxide (NSC 361456). ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8261430/),,2.83,122607,DB00904,Ondansetron
,8261430,t1/2 beta,"Pharmacokinetic parameters for 12 patients analyzed by the 3-compartment model revealed an alpha-half-life (t1/2 alpha) of 2.83 +/- 1.57 (mean +/- SD), a t1/2 beta of 11.9 +/- 4.42, and a t1/2 gamma of 161 +/- 47.1 min, with a mean clearance of 1.86 +/- 0.91 liters/min.",Phase I and pharmacokinetic study of a new antineoplastic agent: pyrazine diazohydroxide (NSC 361456). ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8261430/),,11.9,122608,DB00904,Ondansetron
,8261430,t1/2 gamma,"Pharmacokinetic parameters for 12 patients analyzed by the 3-compartment model revealed an alpha-half-life (t1/2 alpha) of 2.83 +/- 1.57 (mean +/- SD), a t1/2 beta of 11.9 +/- 4.42, and a t1/2 gamma of 161 +/- 47.1 min, with a mean clearance of 1.86 +/- 0.91 liters/min.",Phase I and pharmacokinetic study of a new antineoplastic agent: pyrazine diazohydroxide (NSC 361456). ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8261430/),min,161,122609,DB00904,Ondansetron
,8261430,clearance,"Pharmacokinetic parameters for 12 patients analyzed by the 3-compartment model revealed an alpha-half-life (t1/2 alpha) of 2.83 +/- 1.57 (mean +/- SD), a t1/2 beta of 11.9 +/- 4.42, and a t1/2 gamma of 161 +/- 47.1 min, with a mean clearance of 1.86 +/- 0.91 liters/min.",Phase I and pharmacokinetic study of a new antineoplastic agent: pyrazine diazohydroxide (NSC 361456). ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8261430/),[l] / [min],1.86,122610,DB00904,Ondansetron
,8261430,areas under the plasma drug concentration-time curve,"At the 100- and 133-mg/m2 dose levels, the mean areas under the plasma drug concentration-time curve were 105 and 169 micrograms min/ml, respectively.",Phase I and pharmacokinetic study of a new antineoplastic agent: pyrazine diazohydroxide (NSC 361456). ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8261430/),[min·μg] / [ml],105,122611,DB00904,Ondansetron
,8261430,areas under the plasma drug concentration-time curve,"At the 100- and 133-mg/m2 dose levels, the mean areas under the plasma drug concentration-time curve were 105 and 169 micrograms min/ml, respectively.",Phase I and pharmacokinetic study of a new antineoplastic agent: pyrazine diazohydroxide (NSC 361456). ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8261430/),[min·μg] / [ml],169,122612,DB00904,Ondansetron
,24486335,Cmax,The Cmax (45.8 ng/mL at 0.08 hour) with subcutaneous administration + rHuPH20 was 83% greater and was achieved 68% faster than with intramuscular administration (Cmax = 25 ng/mL at 0.25 hour).,Tolerability and pharmacokinetic properties of ondansetron administered subcutaneously with recombinant human hyaluronidase in minipigs and healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24486335/),[ng] / [ml],45.8,122786,DB00904,Ondansetron
,24486335,Cmax,The Cmax (45.8 ng/mL at 0.08 hour) with subcutaneous administration + rHuPH20 was 83% greater and was achieved 68% faster than with intramuscular administration (Cmax = 25 ng/mL at 0.25 hour).,Tolerability and pharmacokinetic properties of ondansetron administered subcutaneously with recombinant human hyaluronidase in minipigs and healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24486335/),[ng] / [ml],25,122787,DB00904,Ondansetron
,31330277,flow rate,The flow rate was fixed at 300 μL/min and ondansetron and the internal standard were both eluted at 2.3 min.,Highly sensitive HPLC-MS/MS assay for the quantitation of ondansetron in rat plasma and rat brain tissue homogenate following administration of a very low subcutaneous dose. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31330277/),[μl] / [min],300,124846,DB00904,Ondansetron
,1387254,plasma clearance,"Ondansetron plasma clearance averages approximately 0.45 L/h/kg, is similar in young male volunteers and cancer patients undergoing cisplatin-based chemotherapy, and does not change significantly with repeated dosing.",Ondansetron metabolism and pharmacokinetics. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1387254/),[l] / [h·kg],0.45,125671,DB00904,Ondansetron
,1387254,plasma half-life,The result is an increase in mean plasma half-life from 3.5 hours in young volunteers (18-40 years) to 5.5 hours in volunteers over 75 years of age.,Ondansetron metabolism and pharmacokinetics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1387254/),h,3.5,125672,DB00904,Ondansetron
,1387254,plasma half-life,The result is an increase in mean plasma half-life from 3.5 hours in young volunteers (18-40 years) to 5.5 hours in volunteers over 75 years of age.,Ondansetron metabolism and pharmacokinetics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1387254/),h,5.5,125673,DB00904,Ondansetron
,1387254,plasma half-life,"Clearance and volume of distribution are higher in young (7-12 years) cancer patients, resulting in a mean plasma half-life of 2.5 hours.",Ondansetron metabolism and pharmacokinetics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1387254/),h,2.5,125674,DB00904,Ondansetron
,1838490,biodisponibility,"The pharmacokinetics of the drug are as follows: absorption begins about 30 minutes after the administration per os, its biodisponibility is about 60%, its clearance: 20 ml/minute and its elimination half life about 3 hours.","[Ondansetron: a specific 5-HT3 serotonin receptor inhibitor, a new antiemetic in oncology]. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1838490/),%,60,126480,DB00904,Ondansetron
,1838490,clearance,"The pharmacokinetics of the drug are as follows: absorption begins about 30 minutes after the administration per os, its biodisponibility is about 60%, its clearance: 20 ml/minute and its elimination half life about 3 hours.","[Ondansetron: a specific 5-HT3 serotonin receptor inhibitor, a new antiemetic in oncology]. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1838490/),[ml] / [min],20,126481,DB00904,Ondansetron
,1838490,elimination half life,"The pharmacokinetics of the drug are as follows: absorption begins about 30 minutes after the administration per os, its biodisponibility is about 60%, its clearance: 20 ml/minute and its elimination half life about 3 hours.","[Ondansetron: a specific 5-HT3 serotonin receptor inhibitor, a new antiemetic in oncology]. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1838490/),h,3,126482,DB00904,Ondansetron
,10435726,area under the curve (AUC),"Our retrospective study showed that the mean area under the curve (AUC) for both cyclophosphamide (76,600 vs 90,600 microg/ml/min, P=0.001) and cisplatin (525 vs 648 microg/ml/min, P = 0.01) were significantly lower in the ondansetron group when compared with the prochlorperazine group.",Modification of the pharmacokinetics of high-dose cyclophosphamide and cisplatin by antiemetics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10435726/),[μg] / [min·ml],"76,600",127603,DB00904,Ondansetron
,10435726,area under the curve (AUC),"Our retrospective study showed that the mean area under the curve (AUC) for both cyclophosphamide (76,600 vs 90,600 microg/ml/min, P=0.001) and cisplatin (525 vs 648 microg/ml/min, P = 0.01) were significantly lower in the ondansetron group when compared with the prochlorperazine group.",Modification of the pharmacokinetics of high-dose cyclophosphamide and cisplatin by antiemetics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10435726/),[μg] / [min·ml],"90,600",127604,DB00904,Ondansetron
,10435726,area under the curve (AUC),"Our retrospective study showed that the mean area under the curve (AUC) for both cyclophosphamide (76,600 vs 90,600 microg/ml/min, P=0.001) and cisplatin (525 vs 648 microg/ml/min, P = 0.01) were significantly lower in the ondansetron group when compared with the prochlorperazine group.",Modification of the pharmacokinetics of high-dose cyclophosphamide and cisplatin by antiemetics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10435726/),[μg] / [min·ml],525,127605,DB00904,Ondansetron
,10435726,area under the curve (AUC),"Our retrospective study showed that the mean area under the curve (AUC) for both cyclophosphamide (76,600 vs 90,600 microg/ml/min, P=0.001) and cisplatin (525 vs 648 microg/ml/min, P = 0.01) were significantly lower in the ondansetron group when compared with the prochlorperazine group.",Modification of the pharmacokinetics of high-dose cyclophosphamide and cisplatin by antiemetics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10435726/),[μg] / [min·ml],648,127606,DB00904,Ondansetron
,10435726,AUC,"The AUC for BCNU was not significantly different in both groups (544 vs 677, P = 0.43).",Modification of the pharmacokinetics of high-dose cyclophosphamide and cisplatin by antiemetics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10435726/),,544,127607,DB00904,Ondansetron
,10435726,AUC,"The AUC for BCNU was not significantly different in both groups (544 vs 677, P = 0.43).",Modification of the pharmacokinetics of high-dose cyclophosphamide and cisplatin by antiemetics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10435726/),,677,127608,DB00904,Ondansetron
,1531044,plasma clearance,"Mean plasma clearance decreased (young, 0.349 L/hr/kg; elderly, 0.279 L/hr/kg; aged, 0.214 L/hr/kg; p less than 0.05) with increasing age.",Age and gender effects on ondansetron pharmacokinetics: evaluation of healthy aged volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1531044/),[l] / [h·kg],0.349,134173,DB00904,Ondansetron
,1531044,plasma clearance,"Mean plasma clearance decreased (young, 0.349 L/hr/kg; elderly, 0.279 L/hr/kg; aged, 0.214 L/hr/kg; p less than 0.05) with increasing age.",Age and gender effects on ondansetron pharmacokinetics: evaluation of healthy aged volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1531044/),[l] / [h·kg],0.279,134174,DB00904,Ondansetron
,1531044,plasma clearance,"Mean plasma clearance decreased (young, 0.349 L/hr/kg; elderly, 0.279 L/hr/kg; aged, 0.214 L/hr/kg; p less than 0.05) with increasing age.",Age and gender effects on ondansetron pharmacokinetics: evaluation of healthy aged volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1531044/),[l] / [h·kg],0.214,134175,DB00904,Ondansetron
,1531044,Volume of distribution at steady state,"Volume of distribution at steady state was unaffected by age (young, 1.81 L/kg; elderly, 1.94 L/kg; aged, 1.71 L/kg), resulting in increases in mean plasma half-life (young, 3.4 hours; elderly, 4.5 hours; aged, 5.4 hours) and mean absolute bioavailability (young, 57%; elderly, 61%; aged, 69%) with increasing age.",Age and gender effects on ondansetron pharmacokinetics: evaluation of healthy aged volunteers. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1531044/),[l] / [kg],1.81,134176,DB00904,Ondansetron
,1531044,Volume of distribution at steady state,"Volume of distribution at steady state was unaffected by age (young, 1.81 L/kg; elderly, 1.94 L/kg; aged, 1.71 L/kg), resulting in increases in mean plasma half-life (young, 3.4 hours; elderly, 4.5 hours; aged, 5.4 hours) and mean absolute bioavailability (young, 57%; elderly, 61%; aged, 69%) with increasing age.",Age and gender effects on ondansetron pharmacokinetics: evaluation of healthy aged volunteers. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1531044/),[l] / [kg],1.94,134177,DB00904,Ondansetron
,1531044,plasma half-life,"Volume of distribution at steady state was unaffected by age (young, 1.81 L/kg; elderly, 1.94 L/kg; aged, 1.71 L/kg), resulting in increases in mean plasma half-life (young, 3.4 hours; elderly, 4.5 hours; aged, 5.4 hours) and mean absolute bioavailability (young, 57%; elderly, 61%; aged, 69%) with increasing age.",Age and gender effects on ondansetron pharmacokinetics: evaluation of healthy aged volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1531044/),h,3.4,134178,DB00904,Ondansetron
,1531044,plasma half-life,"Volume of distribution at steady state was unaffected by age (young, 1.81 L/kg; elderly, 1.94 L/kg; aged, 1.71 L/kg), resulting in increases in mean plasma half-life (young, 3.4 hours; elderly, 4.5 hours; aged, 5.4 hours) and mean absolute bioavailability (young, 57%; elderly, 61%; aged, 69%) with increasing age.",Age and gender effects on ondansetron pharmacokinetics: evaluation of healthy aged volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1531044/),h,4.5,134179,DB00904,Ondansetron
,1531044,plasma half-life,"Volume of distribution at steady state was unaffected by age (young, 1.81 L/kg; elderly, 1.94 L/kg; aged, 1.71 L/kg), resulting in increases in mean plasma half-life (young, 3.4 hours; elderly, 4.5 hours; aged, 5.4 hours) and mean absolute bioavailability (young, 57%; elderly, 61%; aged, 69%) with increasing age.",Age and gender effects on ondansetron pharmacokinetics: evaluation of healthy aged volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1531044/),h,5.4,134180,DB00904,Ondansetron
,1531044,absolute bioavailability,"Volume of distribution at steady state was unaffected by age (young, 1.81 L/kg; elderly, 1.94 L/kg; aged, 1.71 L/kg), resulting in increases in mean plasma half-life (young, 3.4 hours; elderly, 4.5 hours; aged, 5.4 hours) and mean absolute bioavailability (young, 57%; elderly, 61%; aged, 69%) with increasing age.",Age and gender effects on ondansetron pharmacokinetics: evaluation of healthy aged volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1531044/),%,57,134181,DB00904,Ondansetron
,1531044,absolute bioavailability,"Volume of distribution at steady state was unaffected by age (young, 1.81 L/kg; elderly, 1.94 L/kg; aged, 1.71 L/kg), resulting in increases in mean plasma half-life (young, 3.4 hours; elderly, 4.5 hours; aged, 5.4 hours) and mean absolute bioavailability (young, 57%; elderly, 61%; aged, 69%) with increasing age.",Age and gender effects on ondansetron pharmacokinetics: evaluation of healthy aged volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1531044/),%,61,134182,DB00904,Ondansetron
,1531044,absolute bioavailability,"Volume of distribution at steady state was unaffected by age (young, 1.81 L/kg; elderly, 1.94 L/kg; aged, 1.71 L/kg), resulting in increases in mean plasma half-life (young, 3.4 hours; elderly, 4.5 hours; aged, 5.4 hours) and mean absolute bioavailability (young, 57%; elderly, 61%; aged, 69%) with increasing age.",Age and gender effects on ondansetron pharmacokinetics: evaluation of healthy aged volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1531044/),%,69,134183,DB00904,Ondansetron
,7896539,maximal tolerated dose,The dose-limiting toxicity was myelosuppression and the maximal tolerated dose was 487 mg/m2.,Pyrazine diazohydroxide (NSC-361456). Phase I clinical and pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7896539/),[mg] / [m2],487,146237,DB00904,Ondansetron
,7896539,time to recovery,Hematologic toxicity was delayed and prolonged with median time to recovery about 5 weeks.,Pyrazine diazohydroxide (NSC-361456). Phase I clinical and pharmacokinetic studies. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7896539/),weeks,5,146238,DB00904,Ondansetron
,7896539,k10 half-life,Plasma elimination was fit to one (12/16) or two (4/16) compartment model with a mean k10 half-life of 11.5 min.,Pyrazine diazohydroxide (NSC-361456). Phase I clinical and pharmacokinetic studies. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7896539/),min,11.5,146239,DB00904,Ondansetron
,21290248,AUC,"The kinetic disposition of CYC was enantioselective in patients with breast cancer, with plasma accumulation of the (S)-(-)-CYC enantiomer (AUC 195.0 vs. 174.8 μg h/mL) due to the preferential clearance of the (R)-(+)CYC enantiomer (5.1 vs. 5.7 L/h).",Pharmacokinetics of cyclophosphamide enantiomers in patients with breast cancer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21290248/),[h·μg] / [ml],195.0,154011,DB00904,Ondansetron
,21290248,AUC,"The kinetic disposition of CYC was enantioselective in patients with breast cancer, with plasma accumulation of the (S)-(-)-CYC enantiomer (AUC 195.0 vs. 174.8 μg h/mL) due to the preferential clearance of the (R)-(+)CYC enantiomer (5.1 vs. 5.7 L/h).",Pharmacokinetics of cyclophosphamide enantiomers in patients with breast cancer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21290248/),[h·μg] / [ml],174.8,154012,DB00904,Ondansetron
,21290248,clearance,"The kinetic disposition of CYC was enantioselective in patients with breast cancer, with plasma accumulation of the (S)-(-)-CYC enantiomer (AUC 195.0 vs. 174.8 μg h/mL) due to the preferential clearance of the (R)-(+)CYC enantiomer (5.1 vs. 5.7 L/h).",Pharmacokinetics of cyclophosphamide enantiomers in patients with breast cancer. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21290248/),[l] / [h],5.1,154013,DB00904,Ondansetron
,21290248,clearance,"The kinetic disposition of CYC was enantioselective in patients with breast cancer, with plasma accumulation of the (S)-(-)-CYC enantiomer (AUC 195.0 vs. 174.8 μg h/mL) due to the preferential clearance of the (R)-(+)CYC enantiomer (5.1 vs. 5.7 L/h).",Pharmacokinetics of cyclophosphamide enantiomers in patients with breast cancer. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21290248/),[l] / [h],5.7,154014,DB00904,Ondansetron
,18819031,Flux,"Flux of ondansetron from EVA1802 membranes without PEG6000 was 64.1 +/- 0.6 microg/cm(2.)h, and with 10%w/w of PEG6000 (EVA1802-PEG6000-10) it increased to 194.9 +/- 4.6 microg/cm(2.)h.",Effect of PEG6000 on the in vitro and in vivo transdermal permeation of ondansetron hydrochloride from EVA1802 membranes. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18819031/),[μg] / [)h·cm(2],64.1,155989,DB00904,Ondansetron
,18819031,Flux,"Flux of ondansetron from EVA1802 membranes without PEG6000 was 64.1 +/- 0.6 microg/cm(2.)h, and with 10%w/w of PEG6000 (EVA1802-PEG6000-10) it increased to 194.9 +/- 4.6 microg/cm(2.)h.",Effect of PEG6000 on the in vitro and in vivo transdermal permeation of ondansetron hydrochloride from EVA1802 membranes. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18819031/),[μg] / [)h·cm(2],194.9,155990,DB00904,Ondansetron
,18819031,Flux,"Flux of ondansetron from transdermal patch across rat epidermis was 111.7 +/- 1.3 microg/cm(2.)h, which is about 1.3 times the required flux.",Effect of PEG6000 on the in vitro and in vivo transdermal permeation of ondansetron hydrochloride from EVA1802 membranes. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18819031/),[μg] / [)h·cm(2],111.7,155991,DB00904,Ondansetron
,10778953,apparent topotecan clearance,The apparent topotecan clearance demonstrated substantial interpatient variability but remained unchanged within the same patient in the presence [110 +/- 55.6 liters/ h/m2 (mean +/- SD of eight courses)] or absence of pleural and ascitic fluid [118 +/- 31.1 liters/h/m2 (mean +/- SD of seven courses)].,Topotecan lacks third space sequestration. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10778953/),[l] / [h·m2],110,158377,DB00904,Ondansetron
,10778953,apparent topotecan clearance,The apparent topotecan clearance demonstrated substantial interpatient variability but remained unchanged within the same patient in the presence [110 +/- 55.6 liters/ h/m2 (mean +/- SD of eight courses)] or absence of pleural and ascitic fluid [118 +/- 31.1 liters/h/m2 (mean +/- SD of seven courses)].,Topotecan lacks third space sequestration. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10778953/),[l] / [h·m2],118,158378,DB00904,Ondansetron
,10778953,lag time,"Topotecan penetration into pleural and ascitic fluid demonstrated a mean lag time of 1.61 h (range, 1.37-1.86 h), and ratios with plasma concentration increased with time after dosing in all patients.",Topotecan lacks third space sequestration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10778953/),h,1.61,158379,DB00904,Ondansetron
,9545148,area under the curve (AUC),"The following pharmacokinetic parameters (mean+/-SEM) were obtained for the 8-mg tablet, 16-mg Fattibase suppository, and 16-mg Polybase suppository, respectively: area under the curve (AUC) in men 154.2+/-21.77, 253.4+/-72.3, 304.8+/-62.2 ng x hr/ml; AUC in women 353.6+/-32.7, 561.6+/-103.6, and 768.7+/-117.9 ng x hr/ml; maximum concentration (Cmax) in men 45.5+/-7.0, 40.6+/-10.4, and 51.2+/-6.7 ng/ml; Cmax in women 51.4+/-.8, 47.1+/-3.9, and 82.9+/-6.6 ng/ml.",Relative bioavailability of ondansetron 8-mg oral tablets versus two extemporaneous 16-mg suppositories: formulation and gender differences. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9545148/),[h·ng] / [ml],154.2,159080,DB00904,Ondansetron
,9545148,area under the curve (AUC),"The following pharmacokinetic parameters (mean+/-SEM) were obtained for the 8-mg tablet, 16-mg Fattibase suppository, and 16-mg Polybase suppository, respectively: area under the curve (AUC) in men 154.2+/-21.77, 253.4+/-72.3, 304.8+/-62.2 ng x hr/ml; AUC in women 353.6+/-32.7, 561.6+/-103.6, and 768.7+/-117.9 ng x hr/ml; maximum concentration (Cmax) in men 45.5+/-7.0, 40.6+/-10.4, and 51.2+/-6.7 ng/ml; Cmax in women 51.4+/-.8, 47.1+/-3.9, and 82.9+/-6.6 ng/ml.",Relative bioavailability of ondansetron 8-mg oral tablets versus two extemporaneous 16-mg suppositories: formulation and gender differences. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9545148/),[h·ng] / [ml],253.4,159081,DB00904,Ondansetron
,9545148,area under the curve (AUC),"The following pharmacokinetic parameters (mean+/-SEM) were obtained for the 8-mg tablet, 16-mg Fattibase suppository, and 16-mg Polybase suppository, respectively: area under the curve (AUC) in men 154.2+/-21.77, 253.4+/-72.3, 304.8+/-62.2 ng x hr/ml; AUC in women 353.6+/-32.7, 561.6+/-103.6, and 768.7+/-117.9 ng x hr/ml; maximum concentration (Cmax) in men 45.5+/-7.0, 40.6+/-10.4, and 51.2+/-6.7 ng/ml; Cmax in women 51.4+/-.8, 47.1+/-3.9, and 82.9+/-6.6 ng/ml.",Relative bioavailability of ondansetron 8-mg oral tablets versus two extemporaneous 16-mg suppositories: formulation and gender differences. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9545148/),[h·ng] / [ml],304.8,159082,DB00904,Ondansetron
,9545148,AUC,"The following pharmacokinetic parameters (mean+/-SEM) were obtained for the 8-mg tablet, 16-mg Fattibase suppository, and 16-mg Polybase suppository, respectively: area under the curve (AUC) in men 154.2+/-21.77, 253.4+/-72.3, 304.8+/-62.2 ng x hr/ml; AUC in women 353.6+/-32.7, 561.6+/-103.6, and 768.7+/-117.9 ng x hr/ml; maximum concentration (Cmax) in men 45.5+/-7.0, 40.6+/-10.4, and 51.2+/-6.7 ng/ml; Cmax in women 51.4+/-.8, 47.1+/-3.9, and 82.9+/-6.6 ng/ml.",Relative bioavailability of ondansetron 8-mg oral tablets versus two extemporaneous 16-mg suppositories: formulation and gender differences. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9545148/),[h·ng] / [ml],353.6,159083,DB00904,Ondansetron
,9545148,AUC,"The following pharmacokinetic parameters (mean+/-SEM) were obtained for the 8-mg tablet, 16-mg Fattibase suppository, and 16-mg Polybase suppository, respectively: area under the curve (AUC) in men 154.2+/-21.77, 253.4+/-72.3, 304.8+/-62.2 ng x hr/ml; AUC in women 353.6+/-32.7, 561.6+/-103.6, and 768.7+/-117.9 ng x hr/ml; maximum concentration (Cmax) in men 45.5+/-7.0, 40.6+/-10.4, and 51.2+/-6.7 ng/ml; Cmax in women 51.4+/-.8, 47.1+/-3.9, and 82.9+/-6.6 ng/ml.",Relative bioavailability of ondansetron 8-mg oral tablets versus two extemporaneous 16-mg suppositories: formulation and gender differences. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9545148/),[h·ng] / [ml],561.6,159084,DB00904,Ondansetron
,9545148,AUC,"The following pharmacokinetic parameters (mean+/-SEM) were obtained for the 8-mg tablet, 16-mg Fattibase suppository, and 16-mg Polybase suppository, respectively: area under the curve (AUC) in men 154.2+/-21.77, 253.4+/-72.3, 304.8+/-62.2 ng x hr/ml; AUC in women 353.6+/-32.7, 561.6+/-103.6, and 768.7+/-117.9 ng x hr/ml; maximum concentration (Cmax) in men 45.5+/-7.0, 40.6+/-10.4, and 51.2+/-6.7 ng/ml; Cmax in women 51.4+/-.8, 47.1+/-3.9, and 82.9+/-6.6 ng/ml.",Relative bioavailability of ondansetron 8-mg oral tablets versus two extemporaneous 16-mg suppositories: formulation and gender differences. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9545148/),[h·ng] / [ml],768.7,159085,DB00904,Ondansetron
,9545148,maximum concentration (Cmax),"The following pharmacokinetic parameters (mean+/-SEM) were obtained for the 8-mg tablet, 16-mg Fattibase suppository, and 16-mg Polybase suppository, respectively: area under the curve (AUC) in men 154.2+/-21.77, 253.4+/-72.3, 304.8+/-62.2 ng x hr/ml; AUC in women 353.6+/-32.7, 561.6+/-103.6, and 768.7+/-117.9 ng x hr/ml; maximum concentration (Cmax) in men 45.5+/-7.0, 40.6+/-10.4, and 51.2+/-6.7 ng/ml; Cmax in women 51.4+/-.8, 47.1+/-3.9, and 82.9+/-6.6 ng/ml.",Relative bioavailability of ondansetron 8-mg oral tablets versus two extemporaneous 16-mg suppositories: formulation and gender differences. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9545148/),[ng] / [ml],45.5,159086,DB00904,Ondansetron
,9545148,maximum concentration (Cmax),"The following pharmacokinetic parameters (mean+/-SEM) were obtained for the 8-mg tablet, 16-mg Fattibase suppository, and 16-mg Polybase suppository, respectively: area under the curve (AUC) in men 154.2+/-21.77, 253.4+/-72.3, 304.8+/-62.2 ng x hr/ml; AUC in women 353.6+/-32.7, 561.6+/-103.6, and 768.7+/-117.9 ng x hr/ml; maximum concentration (Cmax) in men 45.5+/-7.0, 40.6+/-10.4, and 51.2+/-6.7 ng/ml; Cmax in women 51.4+/-.8, 47.1+/-3.9, and 82.9+/-6.6 ng/ml.",Relative bioavailability of ondansetron 8-mg oral tablets versus two extemporaneous 16-mg suppositories: formulation and gender differences. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9545148/),[ng] / [ml],40.6,159087,DB00904,Ondansetron
,9545148,maximum concentration (Cmax),"The following pharmacokinetic parameters (mean+/-SEM) were obtained for the 8-mg tablet, 16-mg Fattibase suppository, and 16-mg Polybase suppository, respectively: area under the curve (AUC) in men 154.2+/-21.77, 253.4+/-72.3, 304.8+/-62.2 ng x hr/ml; AUC in women 353.6+/-32.7, 561.6+/-103.6, and 768.7+/-117.9 ng x hr/ml; maximum concentration (Cmax) in men 45.5+/-7.0, 40.6+/-10.4, and 51.2+/-6.7 ng/ml; Cmax in women 51.4+/-.8, 47.1+/-3.9, and 82.9+/-6.6 ng/ml.",Relative bioavailability of ondansetron 8-mg oral tablets versus two extemporaneous 16-mg suppositories: formulation and gender differences. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9545148/),[ng] / [ml],51.2,159088,DB00904,Ondansetron
,9545148,Cmax,"The following pharmacokinetic parameters (mean+/-SEM) were obtained for the 8-mg tablet, 16-mg Fattibase suppository, and 16-mg Polybase suppository, respectively: area under the curve (AUC) in men 154.2+/-21.77, 253.4+/-72.3, 304.8+/-62.2 ng x hr/ml; AUC in women 353.6+/-32.7, 561.6+/-103.6, and 768.7+/-117.9 ng x hr/ml; maximum concentration (Cmax) in men 45.5+/-7.0, 40.6+/-10.4, and 51.2+/-6.7 ng/ml; Cmax in women 51.4+/-.8, 47.1+/-3.9, and 82.9+/-6.6 ng/ml.",Relative bioavailability of ondansetron 8-mg oral tablets versus two extemporaneous 16-mg suppositories: formulation and gender differences. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9545148/),[ng] / [ml],51.4,159089,DB00904,Ondansetron
,9545148,Cmax,"The following pharmacokinetic parameters (mean+/-SEM) were obtained for the 8-mg tablet, 16-mg Fattibase suppository, and 16-mg Polybase suppository, respectively: area under the curve (AUC) in men 154.2+/-21.77, 253.4+/-72.3, 304.8+/-62.2 ng x hr/ml; AUC in women 353.6+/-32.7, 561.6+/-103.6, and 768.7+/-117.9 ng x hr/ml; maximum concentration (Cmax) in men 45.5+/-7.0, 40.6+/-10.4, and 51.2+/-6.7 ng/ml; Cmax in women 51.4+/-.8, 47.1+/-3.9, and 82.9+/-6.6 ng/ml.",Relative bioavailability of ondansetron 8-mg oral tablets versus two extemporaneous 16-mg suppositories: formulation and gender differences. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9545148/),[ng] / [ml],47.1,159090,DB00904,Ondansetron
,9545148,Cmax,"The following pharmacokinetic parameters (mean+/-SEM) were obtained for the 8-mg tablet, 16-mg Fattibase suppository, and 16-mg Polybase suppository, respectively: area under the curve (AUC) in men 154.2+/-21.77, 253.4+/-72.3, 304.8+/-62.2 ng x hr/ml; AUC in women 353.6+/-32.7, 561.6+/-103.6, and 768.7+/-117.9 ng x hr/ml; maximum concentration (Cmax) in men 45.5+/-7.0, 40.6+/-10.4, and 51.2+/-6.7 ng/ml; Cmax in women 51.4+/-.8, 47.1+/-3.9, and 82.9+/-6.6 ng/ml.",Relative bioavailability of ondansetron 8-mg oral tablets versus two extemporaneous 16-mg suppositories: formulation and gender differences. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9545148/),[ng] / [ml],82.9,159091,DB00904,Ondansetron
,9545148,Times to Cmax (Tmax,"Times to Cmax (Tmax; mean+/-SEM) for men were 1.5+/-0.3, 4.4+/-0.5, and 2.9+/-0.3 hours; Tmax for women were 1.8+/-0.3, 4.1+/-0.4, and 4.4+/-0.6 hours for the three formulations, respectively.",Relative bioavailability of ondansetron 8-mg oral tablets versus two extemporaneous 16-mg suppositories: formulation and gender differences. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9545148/),h,1.5,159092,DB00904,Ondansetron
,9545148,Times to Cmax (Tmax,"Times to Cmax (Tmax; mean+/-SEM) for men were 1.5+/-0.3, 4.4+/-0.5, and 2.9+/-0.3 hours; Tmax for women were 1.8+/-0.3, 4.1+/-0.4, and 4.4+/-0.6 hours for the three formulations, respectively.",Relative bioavailability of ondansetron 8-mg oral tablets versus two extemporaneous 16-mg suppositories: formulation and gender differences. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9545148/),h,4.4,159093,DB00904,Ondansetron
,9545148,Times to Cmax (Tmax,"Times to Cmax (Tmax; mean+/-SEM) for men were 1.5+/-0.3, 4.4+/-0.5, and 2.9+/-0.3 hours; Tmax for women were 1.8+/-0.3, 4.1+/-0.4, and 4.4+/-0.6 hours for the three formulations, respectively.",Relative bioavailability of ondansetron 8-mg oral tablets versus two extemporaneous 16-mg suppositories: formulation and gender differences. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9545148/),h,2.9,159094,DB00904,Ondansetron
,9545148,Tmax,"Times to Cmax (Tmax; mean+/-SEM) for men were 1.5+/-0.3, 4.4+/-0.5, and 2.9+/-0.3 hours; Tmax for women were 1.8+/-0.3, 4.1+/-0.4, and 4.4+/-0.6 hours for the three formulations, respectively.",Relative bioavailability of ondansetron 8-mg oral tablets versus two extemporaneous 16-mg suppositories: formulation and gender differences. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9545148/),h,1.8,159095,DB00904,Ondansetron
,9545148,Tmax,"Times to Cmax (Tmax; mean+/-SEM) for men were 1.5+/-0.3, 4.4+/-0.5, and 2.9+/-0.3 hours; Tmax for women were 1.8+/-0.3, 4.1+/-0.4, and 4.4+/-0.6 hours for the three formulations, respectively.",Relative bioavailability of ondansetron 8-mg oral tablets versus two extemporaneous 16-mg suppositories: formulation and gender differences. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9545148/),h,4.1,159096,DB00904,Ondansetron
,9545148,Tmax,"Times to Cmax (Tmax; mean+/-SEM) for men were 1.5+/-0.3, 4.4+/-0.5, and 2.9+/-0.3 hours; Tmax for women were 1.8+/-0.3, 4.1+/-0.4, and 4.4+/-0.6 hours for the three formulations, respectively.",Relative bioavailability of ondansetron 8-mg oral tablets versus two extemporaneous 16-mg suppositories: formulation and gender differences. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9545148/),h,4.4,159097,DB00904,Ondansetron
,18697186,unabsorbed fraction,"After oral administration of ondansetron at a dose of 8 mg/kg, the unabsorbed fraction was 0.0158 of the dose, the extent of absolute oral bioavailability (F) value was 0.0407, and the hepatic and intestinal first-pass effects were 40.0% and 34.2% of the oral dose, respectively.",Dose-independent pharmacokinetics of ondansetron in rats: contribution of hepatic and intestinal first-pass effects to low bioavailability. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18697186/),,0.0158,160095,DB00904,Ondansetron
,18697186,absolute oral bioavailability (F),"After oral administration of ondansetron at a dose of 8 mg/kg, the unabsorbed fraction was 0.0158 of the dose, the extent of absolute oral bioavailability (F) value was 0.0407, and the hepatic and intestinal first-pass effects were 40.0% and 34.2% of the oral dose, respectively.",Dose-independent pharmacokinetics of ondansetron in rats: contribution of hepatic and intestinal first-pass effects to low bioavailability. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18697186/),,0.0407,160096,DB00904,Ondansetron
,18697186,hepatic,"After oral administration of ondansetron at a dose of 8 mg/kg, the unabsorbed fraction was 0.0158 of the dose, the extent of absolute oral bioavailability (F) value was 0.0407, and the hepatic and intestinal first-pass effects were 40.0% and 34.2% of the oral dose, respectively.",Dose-independent pharmacokinetics of ondansetron in rats: contribution of hepatic and intestinal first-pass effects to low bioavailability. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18697186/),%,40.0,160097,DB00904,Ondansetron
,18697186,first-pass effects,"After oral administration of ondansetron at a dose of 8 mg/kg, the unabsorbed fraction was 0.0158 of the dose, the extent of absolute oral bioavailability (F) value was 0.0407, and the hepatic and intestinal first-pass effects were 40.0% and 34.2% of the oral dose, respectively.",Dose-independent pharmacokinetics of ondansetron in rats: contribution of hepatic and intestinal first-pass effects to low bioavailability. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18697186/),%,40.0,160098,DB00904,Ondansetron
,18697186,first-pass effects,"After oral administration of ondansetron at a dose of 8 mg/kg, the unabsorbed fraction was 0.0158 of the dose, the extent of absolute oral bioavailability (F) value was 0.0407, and the hepatic and intestinal first-pass effects were 40.0% and 34.2% of the oral dose, respectively.",Dose-independent pharmacokinetics of ondansetron in rats: contribution of hepatic and intestinal first-pass effects to low bioavailability. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18697186/),%,34.2,160099,DB00904,Ondansetron
,18697186,equilibrium plasma-to-blood cells partition ratio,The equilibrium plasma-to-blood cells partition ratio of ondansetron was 1.74-5.31.,Dose-independent pharmacokinetics of ondansetron in rats: contribution of hepatic and intestinal first-pass effects to low bioavailability. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18697186/),,1.74-5.31,160100,DB00904,Ondansetron
,18697186,Protein binding,Protein binding of ondansetron to fresh rat plasma was 53.2%.,Dose-independent pharmacokinetics of ondansetron in rats: contribution of hepatic and intestinal first-pass effects to low bioavailability. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18697186/),%,53.2,160101,DB00904,Ondansetron
,7929872,Absolute bioavailability,"Absolute bioavailability after the oral dosing on day 1 was 87.5 +/- 31.3%, and on day 5 was 85.2 +/- 22.1% (P > .05).",Oral ondansetron pharmacokinetics: the effect of chemotherapy. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7929872/),%,87.5,162420,DB00904,Ondansetron
,7929872,Absolute bioavailability,"Absolute bioavailability after the oral dosing on day 1 was 87.5 +/- 31.3%, and on day 5 was 85.2 +/- 22.1% (P > .05).",Oral ondansetron pharmacokinetics: the effect of chemotherapy. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7929872/),%,85.2,162421,DB00904,Ondansetron
,7929872,AUC,"Mean values of AUC, Cmax, Tmax, and half life on days 1 and 5 were 399 +/- 275 and 381 +/- 222 ng.hour/mL, 53.3 +/- 26.8 and 43.6 +/- 21.7 ng/mL, 1.9 +/- 1.4 and 2 +/- 1.4 hours, and 5.21 +/- 1.78 and 6.19 +/- 1.99 hours, respectively.",Oral ondansetron pharmacokinetics: the effect of chemotherapy. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7929872/),[h·ng] / [ml],399,162422,DB00904,Ondansetron
,7929872,Cmax,"Mean values of AUC, Cmax, Tmax, and half life on days 1 and 5 were 399 +/- 275 and 381 +/- 222 ng.hour/mL, 53.3 +/- 26.8 and 43.6 +/- 21.7 ng/mL, 1.9 +/- 1.4 and 2 +/- 1.4 hours, and 5.21 +/- 1.78 and 6.19 +/- 1.99 hours, respectively.",Oral ondansetron pharmacokinetics: the effect of chemotherapy. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7929872/),[h·ng] / [ml],381,162423,DB00904,Ondansetron
,7929872,Cmax,"Mean values of AUC, Cmax, Tmax, and half life on days 1 and 5 were 399 +/- 275 and 381 +/- 222 ng.hour/mL, 53.3 +/- 26.8 and 43.6 +/- 21.7 ng/mL, 1.9 +/- 1.4 and 2 +/- 1.4 hours, and 5.21 +/- 1.78 and 6.19 +/- 1.99 hours, respectively.",Oral ondansetron pharmacokinetics: the effect of chemotherapy. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7929872/),h,1.9,162424,DB00904,Ondansetron
,7929872,Tmax,"Mean values of AUC, Cmax, Tmax, and half life on days 1 and 5 were 399 +/- 275 and 381 +/- 222 ng.hour/mL, 53.3 +/- 26.8 and 43.6 +/- 21.7 ng/mL, 1.9 +/- 1.4 and 2 +/- 1.4 hours, and 5.21 +/- 1.78 and 6.19 +/- 1.99 hours, respectively.",Oral ondansetron pharmacokinetics: the effect of chemotherapy. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7929872/),[h·ng] / [ml],381,162425,DB00904,Ondansetron
,7929872,Tmax,"Mean values of AUC, Cmax, Tmax, and half life on days 1 and 5 were 399 +/- 275 and 381 +/- 222 ng.hour/mL, 53.3 +/- 26.8 and 43.6 +/- 21.7 ng/mL, 1.9 +/- 1.4 and 2 +/- 1.4 hours, and 5.21 +/- 1.78 and 6.19 +/- 1.99 hours, respectively.",Oral ondansetron pharmacokinetics: the effect of chemotherapy. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7929872/),h,1.9,162426,DB00904,Ondansetron
,7929872,half life,"Mean values of AUC, Cmax, Tmax, and half life on days 1 and 5 were 399 +/- 275 and 381 +/- 222 ng.hour/mL, 53.3 +/- 26.8 and 43.6 +/- 21.7 ng/mL, 1.9 +/- 1.4 and 2 +/- 1.4 hours, and 5.21 +/- 1.78 and 6.19 +/- 1.99 hours, respectively.",Oral ondansetron pharmacokinetics: the effect of chemotherapy. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7929872/),h,2,162427,DB00904,Ondansetron
,7929872,half life,"Mean values of AUC, Cmax, Tmax, and half life on days 1 and 5 were 399 +/- 275 and 381 +/- 222 ng.hour/mL, 53.3 +/- 26.8 and 43.6 +/- 21.7 ng/mL, 1.9 +/- 1.4 and 2 +/- 1.4 hours, and 5.21 +/- 1.78 and 6.19 +/- 1.99 hours, respectively.",Oral ondansetron pharmacokinetics: the effect of chemotherapy. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7929872/),h,5.21,162428,DB00904,Ondansetron
,7929872,half life,"Mean values of AUC, Cmax, Tmax, and half life on days 1 and 5 were 399 +/- 275 and 381 +/- 222 ng.hour/mL, 53.3 +/- 26.8 and 43.6 +/- 21.7 ng/mL, 1.9 +/- 1.4 and 2 +/- 1.4 hours, and 5.21 +/- 1.78 and 6.19 +/- 1.99 hours, respectively.",Oral ondansetron pharmacokinetics: the effect of chemotherapy. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7929872/),h,6.19,162429,DB00904,Ondansetron
,26316701,relative bioavailability,The mean (standard derivation [SD]) relative bioavailability was 96.5 (23.7%).,Pharmacokinetics and bioavailability study of two ondansetron oral soluble film formulations in fasting healthy male Chinese volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26316701/),,96.5,167493,DB00904,Ondansetron
,27195435,V1 (,"The pharmacokinetic parameter estimates were V1 (l) = 5.12, V2 (l) = 108, CL (l⋅min(-1) ) = 0.08 + (59⋅age(-1) ) × 0.09, Q (l⋅min(-1) ) = 1.42.",Population pharmacokinetics and prophylactic anti-emetic efficacy of ramosetron in surgical patients. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27195435/),l,5.12,172354,DB00904,Ondansetron
,27195435,V2 (,"The pharmacokinetic parameter estimates were V1 (l) = 5.12, V2 (l) = 108, CL (l⋅min(-1) ) = 0.08 + (59⋅age(-1) ) × 0.09, Q (l⋅min(-1) ) = 1.42.",Population pharmacokinetics and prophylactic anti-emetic efficacy of ramosetron in surgical patients. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27195435/),l,108,172355,DB00904,Ondansetron
,27195435,CL,"The pharmacokinetic parameter estimates were V1 (l) = 5.12, V2 (l) = 108, CL (l⋅min(-1) ) = 0.08 + (59⋅age(-1) ) × 0.09, Q (l⋅min(-1) ) = 1.42.",Population pharmacokinetics and prophylactic anti-emetic efficacy of ramosetron in surgical patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27195435/),[l] / [min],0,172356,DB00904,Ondansetron
,27195435,Q,"The pharmacokinetic parameter estimates were V1 (l) = 5.12, V2 (l) = 108, CL (l⋅min(-1) ) = 0.08 + (59⋅age(-1) ) × 0.09, Q (l⋅min(-1) ) = 1.42.",Population pharmacokinetics and prophylactic anti-emetic efficacy of ramosetron in surgical patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27195435/),[l] / [min],1.42,172357,DB00904,Ondansetron
,15139789,terminal elimination half-life,"Intravenously administered palonosetron has a linear pharmacokinetic profile, with a long terminal elimination half-life ( approximate, equals 40 hours) and moderate (62%) plasma protein binding.",Palonosetron. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15139789/),h,40,174042,DB00904,Ondansetron
,15899109,plasma elimination half-life,"With and without aprepitant coadministration, respectively, mean plasma elimination half-life was 40 hours and 43 hours (difference: -3.0 hours; p = 0.348), mean total body clearance was 130 mL/min and 136 mL/min (difference: -5.6 mL/min; p = 0.735), and mean volume of distribution at steady-state was 410.9 L and 442.3 L (difference: -31.4 L; p = 0.463).",Pharmacokinetics of palonosetron in combination with aprepitant in healthy volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15899109/),h,40,174671,DB00904,Ondansetron
,15899109,plasma elimination half-life,"With and without aprepitant coadministration, respectively, mean plasma elimination half-life was 40 hours and 43 hours (difference: -3.0 hours; p = 0.348), mean total body clearance was 130 mL/min and 136 mL/min (difference: -5.6 mL/min; p = 0.735), and mean volume of distribution at steady-state was 410.9 L and 442.3 L (difference: -31.4 L; p = 0.463).",Pharmacokinetics of palonosetron in combination with aprepitant in healthy volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15899109/),h,43,174672,DB00904,Ondansetron
,15899109,total body clearance,"With and without aprepitant coadministration, respectively, mean plasma elimination half-life was 40 hours and 43 hours (difference: -3.0 hours; p = 0.348), mean total body clearance was 130 mL/min and 136 mL/min (difference: -5.6 mL/min; p = 0.735), and mean volume of distribution at steady-state was 410.9 L and 442.3 L (difference: -31.4 L; p = 0.463).",Pharmacokinetics of palonosetron in combination with aprepitant in healthy volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15899109/),[ml] / [min],130,174673,DB00904,Ondansetron
,15899109,total body clearance,"With and without aprepitant coadministration, respectively, mean plasma elimination half-life was 40 hours and 43 hours (difference: -3.0 hours; p = 0.348), mean total body clearance was 130 mL/min and 136 mL/min (difference: -5.6 mL/min; p = 0.735), and mean volume of distribution at steady-state was 410.9 L and 442.3 L (difference: -31.4 L; p = 0.463).",Pharmacokinetics of palonosetron in combination with aprepitant in healthy volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15899109/),[ml] / [min],136,174674,DB00904,Ondansetron
,15899109,volume of distribution at steady-state,"With and without aprepitant coadministration, respectively, mean plasma elimination half-life was 40 hours and 43 hours (difference: -3.0 hours; p = 0.348), mean total body clearance was 130 mL/min and 136 mL/min (difference: -5.6 mL/min; p = 0.735), and mean volume of distribution at steady-state was 410.9 L and 442.3 L (difference: -31.4 L; p = 0.463).",Pharmacokinetics of palonosetron in combination with aprepitant in healthy volunteers. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15899109/),l,410.9,174675,DB00904,Ondansetron
,15899109,volume of distribution at steady-state,"With and without aprepitant coadministration, respectively, mean plasma elimination half-life was 40 hours and 43 hours (difference: -3.0 hours; p = 0.348), mean total body clearance was 130 mL/min and 136 mL/min (difference: -5.6 mL/min; p = 0.735), and mean volume of distribution at steady-state was 410.9 L and 442.3 L (difference: -31.4 L; p = 0.463).",Pharmacokinetics of palonosetron in combination with aprepitant in healthy volunteers. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15899109/),l,442.3,174676,DB00904,Ondansetron
,15553104,retention times,"The retention times of ondansetron and internal standard (propranolol hydrochloride, CAS 318-98-9) were 9.38 and 13.40 min, respectively.","A rapid, sensitive and validated method for the determination of ondansetron in human plasma by reversed-phase high-pressure liquid chromatography. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15553104/),min,9.38,176969,DB00904,Ondansetron
,15553104,retention times,"The retention times of ondansetron and internal standard (propranolol hydrochloride, CAS 318-98-9) were 9.38 and 13.40 min, respectively.","A rapid, sensitive and validated method for the determination of ondansetron in human plasma by reversed-phase high-pressure liquid chromatography. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15553104/),min,13.40,176970,DB00904,Ondansetron
,10850615,In vivo recovery,"In vivo recovery (32.52 +/- 1.8%) of the probe was assessed with the retrodialysis method, which was used to calculate the ON concentration in the dermis.",Microdialysis sampling coupled to HPLC for transdermal delivery study of ondansetron hydrochloride in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10850615/),%,32.52,177553,DB00904,Ondansetron
,10850615,steady-state delivery rate,"Oleic acid at the concentrations of 2% and 5% (w/v) increased the steady-state delivery rate from 0.001 to 0.030 and 0.058 microg/h, respectively.",Microdialysis sampling coupled to HPLC for transdermal delivery study of ondansetron hydrochloride in rats. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10850615/),[μg] / [h],0.001,177554,DB00904,Ondansetron
,10850615,steady-state delivery rate,"Oleic acid at the concentrations of 2% and 5% (w/v) increased the steady-state delivery rate from 0.001 to 0.030 and 0.058 microg/h, respectively.",Microdialysis sampling coupled to HPLC for transdermal delivery study of ondansetron hydrochloride in rats. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10850615/),[μg] / [h],0.030,177555,DB00904,Ondansetron
,10850615,steady-state delivery rate,"Oleic acid at the concentrations of 2% and 5% (w/v) increased the steady-state delivery rate from 0.001 to 0.030 and 0.058 microg/h, respectively.",Microdialysis sampling coupled to HPLC for transdermal delivery study of ondansetron hydrochloride in rats. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10850615/),[μg] / [h],0.058,177556,DB00904,Ondansetron
,1365869,concentrations,Ondansetron concentrations ranged from 39.5-147 ng ml-1 in plasma and from 2.6-15.4 ng ml-1 in CSF.,Concentration of ondansetron in cerebrospinal fluid following oral dosing in volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1365869/),[ng] / [ml],39.5-147,181826,DB00904,Ondansetron
,1365869,concentrations,Ondansetron concentrations ranged from 39.5-147 ng ml-1 in plasma and from 2.6-15.4 ng ml-1 in CSF.,Concentration of ondansetron in cerebrospinal fluid following oral dosing in volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1365869/),[ng] / [ml],2.6-15.4,181827,DB00904,Ondansetron
,16317293,maximum plasma concentration,Mean maximum plasma concentration was 12.5 min.,Plasma kinetics of procarbazine and azo-procarbazine in humans. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16317293/),min,12.5,184322,DB00904,Ondansetron
,16317293,apparent oral systemic clearance,"The mean apparent oral systemic clearance and the plasma elimination half-life were estimated at 35.8 l/min and 9.2 min, respectively.",Plasma kinetics of procarbazine and azo-procarbazine in humans. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16317293/),[l] / [min],35.8,184323,DB00904,Ondansetron
,16317293,plasma elimination half-life,"The mean apparent oral systemic clearance and the plasma elimination half-life were estimated at 35.8 l/min and 9.2 min, respectively.",Plasma kinetics of procarbazine and azo-procarbazine in humans. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16317293/),min,9.2,184324,DB00904,Ondansetron
,16317293,Cmax,The mean Cmax and AUC ratios of azo-PCB/PCB were estimated at 5.5 and 45.2.,Plasma kinetics of procarbazine and azo-procarbazine in humans. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16317293/),,5.5,184325,DB00904,Ondansetron
,16317293,AUC ratios,The mean Cmax and AUC ratios of azo-PCB/PCB were estimated at 5.5 and 45.2.,Plasma kinetics of procarbazine and azo-procarbazine in humans. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16317293/),,45.2,184326,DB00904,Ondansetron
,31350675,polydispersity index,"The optimized NLCs formulation exhibited particle size of 185.2 ± 1.9 nm, polydispersity index of 0.214 ± 0.006, EE of 93.2 ± 0.5%, and DL of 10.43 ± 0.05% as well as an in vitro sustained-release profile of ODS.",Preparation of Ondansetron Hydrochloride-Loaded Nanostructured Lipid Carriers Using Solvent Injection Method for Enhancement of Pharmacokinetic Properties. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31350675/),,0.214,185455,DB00904,Ondansetron
,31350675,EE,"The optimized NLCs formulation exhibited particle size of 185.2 ± 1.9 nm, polydispersity index of 0.214 ± 0.006, EE of 93.2 ± 0.5%, and DL of 10.43 ± 0.05% as well as an in vitro sustained-release profile of ODS.",Preparation of Ondansetron Hydrochloride-Loaded Nanostructured Lipid Carriers Using Solvent Injection Method for Enhancement of Pharmacokinetic Properties. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31350675/),%,93.2,185456,DB00904,Ondansetron
,31350675,DL,"The optimized NLCs formulation exhibited particle size of 185.2 ± 1.9 nm, polydispersity index of 0.214 ± 0.006, EE of 93.2 ± 0.5%, and DL of 10.43 ± 0.05% as well as an in vitro sustained-release profile of ODS.",Preparation of Ondansetron Hydrochloride-Loaded Nanostructured Lipid Carriers Using Solvent Injection Method for Enhancement of Pharmacokinetic Properties. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31350675/),%,10.43,185457,DB00904,Ondansetron
<,22139694,friability,The tablets' hardness was maintained in the range of 2-3 kg and friability was <1% for all batches.,Formulation and in vivo evaluation of ondansetron orally disintegrating tablets using different superdisintegrants. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22139694/),%,1,191828,DB00904,Ondansetron
,18299256,flow rate,"HPLC separation was performed on an ovomucoid column using an isocratic mobile phase of methanol-5 mM ammonium acetate-acetic acid (20:80:0.02, v/v/v) at a flow rate of 0.40 mL/min.",Quantitative determination of ondansetron in human plasma by enantioselective liquid chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18299256/),[ml] / [min],0.40,193848,DB00904,Ondansetron
,24330064,Bioavailability,Bioavailability of ondansetron was 32% (oral) and 75% (subcutaneous).,"Oral, subcutaneous, and intravenous pharmacokinetics of ondansetron in healthy cats. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24330064/),%,32,198664,DB00904,Ondansetron
,24330064,Bioavailability,Bioavailability of ondansetron was 32% (oral) and 75% (subcutaneous).,"Oral, subcutaneous, and intravenous pharmacokinetics of ondansetron in healthy cats. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24330064/),%,75,198665,DB00904,Ondansetron
,24330064,elimination half-life,"Calculated elimination half-life of ondansetron was 1.84 ± 0.58 h (intravenous), 1.18 ± 0.27 h (oral) and 3.17 ± 0.53 h (subcutaneous).","Oral, subcutaneous, and intravenous pharmacokinetics of ondansetron in healthy cats. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/24330064/),h,1.84,198666,DB00904,Ondansetron
,24330064,elimination half-life,"Calculated elimination half-life of ondansetron was 1.84 ± 0.58 h (intravenous), 1.18 ± 0.27 h (oral) and 3.17 ± 0.53 h (subcutaneous).","Oral, subcutaneous, and intravenous pharmacokinetics of ondansetron in healthy cats. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/24330064/),h,1.18,198667,DB00904,Ondansetron
,24330064,elimination half-life,"Calculated elimination half-life of ondansetron was 1.84 ± 0.58 h (intravenous), 1.18 ± 0.27 h (oral) and 3.17 ± 0.53 h (subcutaneous).","Oral, subcutaneous, and intravenous pharmacokinetics of ondansetron in healthy cats. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/24330064/),h,3.17,198668,DB00904,Ondansetron
,27374186,area under the plasma concentration-time curve,"Ondansetron area under the plasma concentration-time curve decreased progressively across gestation (634 ng hr/ml in early pregnancy, 553 ng hr/ml in mid-pregnancy, and 387 ng hr/ml in late pregnancy), with a corresponding increase in apparent oral clearance (12.6 L/hr in early-pregnancy, 14.5 L/hr in mid-pregnancy, and 20.7 L/hr in late-pregnancy).",Ondansetron Exposure Changes in a Pregnant Woman. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27374186/),[h·ng] / [ml],634,200266,DB00904,Ondansetron
,27374186,area under the plasma concentration-time curve,"Ondansetron area under the plasma concentration-time curve decreased progressively across gestation (634 ng hr/ml in early pregnancy, 553 ng hr/ml in mid-pregnancy, and 387 ng hr/ml in late pregnancy), with a corresponding increase in apparent oral clearance (12.6 L/hr in early-pregnancy, 14.5 L/hr in mid-pregnancy, and 20.7 L/hr in late-pregnancy).",Ondansetron Exposure Changes in a Pregnant Woman. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27374186/),[h·ng] / [ml],553,200267,DB00904,Ondansetron
,27374186,area under the plasma concentration-time curve,"Ondansetron area under the plasma concentration-time curve decreased progressively across gestation (634 ng hr/ml in early pregnancy, 553 ng hr/ml in mid-pregnancy, and 387 ng hr/ml in late pregnancy), with a corresponding increase in apparent oral clearance (12.6 L/hr in early-pregnancy, 14.5 L/hr in mid-pregnancy, and 20.7 L/hr in late-pregnancy).",Ondansetron Exposure Changes in a Pregnant Woman. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27374186/),[h·ng] / [ml],387,200268,DB00904,Ondansetron
,27374186,apparent oral clearance,"Ondansetron area under the plasma concentration-time curve decreased progressively across gestation (634 ng hr/ml in early pregnancy, 553 ng hr/ml in mid-pregnancy, and 387 ng hr/ml in late pregnancy), with a corresponding increase in apparent oral clearance (12.6 L/hr in early-pregnancy, 14.5 L/hr in mid-pregnancy, and 20.7 L/hr in late-pregnancy).",Ondansetron Exposure Changes in a Pregnant Woman. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27374186/),[l] / [h],12.6,200269,DB00904,Ondansetron
,27374186,apparent oral clearance,"Ondansetron area under the plasma concentration-time curve decreased progressively across gestation (634 ng hr/ml in early pregnancy, 553 ng hr/ml in mid-pregnancy, and 387 ng hr/ml in late pregnancy), with a corresponding increase in apparent oral clearance (12.6 L/hr in early-pregnancy, 14.5 L/hr in mid-pregnancy, and 20.7 L/hr in late-pregnancy).",Ondansetron Exposure Changes in a Pregnant Woman. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27374186/),[l] / [h],14.5,200270,DB00904,Ondansetron
,27374186,apparent oral clearance,"Ondansetron area under the plasma concentration-time curve decreased progressively across gestation (634 ng hr/ml in early pregnancy, 553 ng hr/ml in mid-pregnancy, and 387 ng hr/ml in late pregnancy), with a corresponding increase in apparent oral clearance (12.6 L/hr in early-pregnancy, 14.5 L/hr in mid-pregnancy, and 20.7 L/hr in late-pregnancy).",Ondansetron Exposure Changes in a Pregnant Woman. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27374186/),[l] / [h],20.7,200271,DB00904,Ondansetron
,7965657,Cmax,"The tablet and solution formulations were bioequivalent, as confirmed by similarities in mean Cmax (26.3 vs 27.7 ng/mL), Tmax (1.79 vs 1.70 h), and AUC (166.0 vs 167.3 ng.h/mL) values.","Ondansetron absorption in adults: effect of dosage form, food, and antacids. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7965657/),[ng] / [ml],26.3,202368,DB00904,Ondansetron
,7965657,Cmax,"The tablet and solution formulations were bioequivalent, as confirmed by similarities in mean Cmax (26.3 vs 27.7 ng/mL), Tmax (1.79 vs 1.70 h), and AUC (166.0 vs 167.3 ng.h/mL) values.","Ondansetron absorption in adults: effect of dosage form, food, and antacids. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7965657/),[ng] / [ml],27.7,202369,DB00904,Ondansetron
,7965657,Tmax,"The tablet and solution formulations were bioequivalent, as confirmed by similarities in mean Cmax (26.3 vs 27.7 ng/mL), Tmax (1.79 vs 1.70 h), and AUC (166.0 vs 167.3 ng.h/mL) values.","Ondansetron absorption in adults: effect of dosage form, food, and antacids. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7965657/),h,1.79,202370,DB00904,Ondansetron
,7965657,Tmax,"The tablet and solution formulations were bioequivalent, as confirmed by similarities in mean Cmax (26.3 vs 27.7 ng/mL), Tmax (1.79 vs 1.70 h), and AUC (166.0 vs 167.3 ng.h/mL) values.","Ondansetron absorption in adults: effect of dosage form, food, and antacids. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7965657/),h,1.70,202371,DB00904,Ondansetron
,7965657,AUC,"The tablet and solution formulations were bioequivalent, as confirmed by similarities in mean Cmax (26.3 vs 27.7 ng/mL), Tmax (1.79 vs 1.70 h), and AUC (166.0 vs 167.3 ng.h/mL) values.","Ondansetron absorption in adults: effect of dosage form, food, and antacids. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7965657/),[h·ng] / [ml],166.0,202372,DB00904,Ondansetron
,7965657,AUC,"The tablet and solution formulations were bioequivalent, as confirmed by similarities in mean Cmax (26.3 vs 27.7 ng/mL), Tmax (1.79 vs 1.70 h), and AUC (166.0 vs 167.3 ng.h/mL) values.","Ondansetron absorption in adults: effect of dosage form, food, and antacids. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7965657/),[h·ng] / [ml],167.3,202373,DB00904,Ondansetron
,7965657,AUC,"In another randomized, open-label, crossover study in 12 healthy male subjects, the bioavailability of an 8-mg ondansetron tablet administered 5 min after a standard meal was slightly but significantly greater than in fasted subjects, as indicated by comparative mean AUC values [201.4 ng.h/mL (fed) vs 172.5 ng.h/mL (fasted)].","Ondansetron absorption in adults: effect of dosage form, food, and antacids. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7965657/),[h·ng] / [ml],201.4,202374,DB00904,Ondansetron
,7965657,AUC,"In another randomized, open-label, crossover study in 12 healthy male subjects, the bioavailability of an 8-mg ondansetron tablet administered 5 min after a standard meal was slightly but significantly greater than in fasted subjects, as indicated by comparative mean AUC values [201.4 ng.h/mL (fed) vs 172.5 ng.h/mL (fasted)].","Ondansetron absorption in adults: effect of dosage form, food, and antacids. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7965657/),[h·ng] / [ml],172.5,202375,DB00904,Ondansetron
,8275479,mean residence times,"The Cmax for the active metabolite of CPT-11, 7-ethyl-10-hydroxycamptothecin (SN-38), was achieved at 2.2 +/- 0.1 h after treatment, and mean residence times for both CPT-11 and SN-38 were long, 9.1 and 10.0 h, respectively.",Phase I and pharmacological study of the novel topoisomerase I inhibitor 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin (CPT-11) administered as a ninety-minute infusion every 3 weeks. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8275479/),h,9.1,202531,DB00904,Ondansetron
,8275479,mean residence times,"The Cmax for the active metabolite of CPT-11, 7-ethyl-10-hydroxycamptothecin (SN-38), was achieved at 2.2 +/- 0.1 h after treatment, and mean residence times for both CPT-11 and SN-38 were long, 9.1 and 10.0 h, respectively.",Phase I and pharmacological study of the novel topoisomerase I inhibitor 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin (CPT-11) administered as a ninety-minute infusion every 3 weeks. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8275479/),h,10.0,202532,DB00904,Ondansetron
,10396331,bioavailability,"Also, orally-administered azasetron has shown to be absorbed and/or secreted by the saturable transport mechanism in the small intestine, resulting in good bioavailability as approximately 90%.","[Pharmacokinetics of azasetron (Serotone), a selective 5-HT3 receptor antagonist]. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10396331/),%,90,204200,DB00904,Ondansetron
,1425620,tmax,Ondansetron is rapidly absorbed after oral administration (tmax 1.9 h) with an absolute bioavailability of around 60%.,Clinical pharmacology of ondansetron in postoperative nausea and vomiting. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1425620/),h,1.9,210774,DB00904,Ondansetron
,1425620,absolute bioavailability,Ondansetron is rapidly absorbed after oral administration (tmax 1.9 h) with an absolute bioavailability of around 60%.,Clinical pharmacology of ondansetron in postoperative nausea and vomiting. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1425620/),%,60,210775,DB00904,Ondansetron
,1425620,terminal elimination half-life,Its terminal elimination half-life is 3.5 h and it is extensively hepatically metabolized.,Clinical pharmacology of ondansetron in postoperative nausea and vomiting. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1425620/),h,3.5,210776,DB00904,Ondansetron
,1425620,Plasma clearance,Plasma clearance is 0.38 litre h-1 kg-1 and volume of distribution is 1.8 litre kg-1.,Clinical pharmacology of ondansetron in postoperative nausea and vomiting. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1425620/),[l] / [h·kg],0.38,210777,DB00904,Ondansetron
,1425620,volume of distribution,Plasma clearance is 0.38 litre h-1 kg-1 and volume of distribution is 1.8 litre kg-1.,Clinical pharmacology of ondansetron in postoperative nausea and vomiting. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1425620/),[l] / [kg],1.8,210778,DB00904,Ondansetron
,26825640,Cmax,Ondansetron treatment caused a statistically significantly higher Cmax of metformin compared with placebo (18.3 ± 5.05 versus 15.2 ± 3.23; P = 0.006) and apparently decreased the renal clearance of metformin by 37% as compared with placebo (P = 0.001).,Effect of Ondansetron on Metformin Pharmacokinetics and Response in Healthy Subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26825640/),,18.3,212282,DB00904,Ondansetron
,26825640,Cmax,Ondansetron treatment caused a statistically significantly higher Cmax of metformin compared with placebo (18.3 ± 5.05 versus 15.2 ± 3.23; P = 0.006) and apparently decreased the renal clearance of metformin by 37% as compared with placebo (P = 0.001).,Effect of Ondansetron on Metformin Pharmacokinetics and Response in Healthy Subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26825640/),,15.2,212283,DB00904,Ondansetron
,26825640,glucose,"Interestingly, ondansetron treatment also statistically significantly improved glucose tolerance in subjects, as indicated by the smaller glucose area under the curve in the oral glucose tolerance test (10.4 ± 1.43) as compared with placebo (11.5 ± 2.29 mmol∙mg/l) (P = 0.020).",Effect of Ondansetron on Metformin Pharmacokinetics and Response in Healthy Subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26825640/),[mmol∙mg] / [l],10.4,212284,DB00904,Ondansetron
,26825640,glucose,"Interestingly, ondansetron treatment also statistically significantly improved glucose tolerance in subjects, as indicated by the smaller glucose area under the curve in the oral glucose tolerance test (10.4 ± 1.43) as compared with placebo (11.5 ± 2.29 mmol∙mg/l) (P = 0.020).",Effect of Ondansetron on Metformin Pharmacokinetics and Response in Healthy Subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26825640/),[mmol∙mg] / [l],11.5,212285,DB00904,Ondansetron
,26825640,area under the curve,"Interestingly, ondansetron treatment also statistically significantly improved glucose tolerance in subjects, as indicated by the smaller glucose area under the curve in the oral glucose tolerance test (10.4 ± 1.43) as compared with placebo (11.5 ± 2.29 mmol∙mg/l) (P = 0.020).",Effect of Ondansetron on Metformin Pharmacokinetics and Response in Healthy Subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26825640/),[mmol∙mg] / [l],10.4,212286,DB00904,Ondansetron
,26825640,area under the curve,"Interestingly, ondansetron treatment also statistically significantly improved glucose tolerance in subjects, as indicated by the smaller glucose area under the curve in the oral glucose tolerance test (10.4 ± 1.43) as compared with placebo (11.5 ± 2.29 mmol∙mg/l) (P = 0.020).",Effect of Ondansetron on Metformin Pharmacokinetics and Response in Healthy Subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26825640/),[mmol∙mg] / [l],11.5,212287,DB00904,Ondansetron
,23835420,transport,Morphine showed low transporter-independent membrane permeability (0.5 × 10⁻⁶ cm/s).,Morphine is a substrate of the organic cation transporter OCT1 and polymorphisms in OCT1 gene affect morphine pharmacokinetics after codeine administration. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23835420/),[cm] / [s],0.5 × 10⁻⁶,218864,DB00904,Ondansetron
,23835420,membrane permeability,Morphine showed low transporter-independent membrane permeability (0.5 × 10⁻⁶ cm/s).,Morphine is a substrate of the organic cation transporter OCT1 and polymorphisms in OCT1 gene affect morphine pharmacokinetics after codeine administration. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23835420/),[cm] / [s],0.5 × 10⁻⁶,218865,DB00904,Ondansetron
,23835420,KM,"The increase was concentration-dependent and followed Michaelis-Menten kinetics (KM = 3.4 μM, VMAX = 27 pmol/min/mg protein).",Morphine is a substrate of the organic cation transporter OCT1 and polymorphisms in OCT1 gene affect morphine pharmacokinetics after codeine administration. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23835420/),μM,3.4,218866,DB00904,Ondansetron
,23835420,VMAX,"The increase was concentration-dependent and followed Michaelis-Menten kinetics (KM = 3.4 μM, VMAX = 27 pmol/min/mg protein).",Morphine is a substrate of the organic cation transporter OCT1 and polymorphisms in OCT1 gene affect morphine pharmacokinetics after codeine administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23835420/),[pM] / [mg·min],27,218867,DB00904,Ondansetron
,23835420,transporter-independent,Codeine itself had high transporter-independent membrane permeability (8.2 × 10⁻⁶ cm/s).,Morphine is a substrate of the organic cation transporter OCT1 and polymorphisms in OCT1 gene affect morphine pharmacokinetics after codeine administration. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23835420/),[cm] / [s],8.2 × 10⁻⁶,218868,DB00904,Ondansetron
,23835420,membrane permeability,Codeine itself had high transporter-independent membrane permeability (8.2 × 10⁻⁶ cm/s).,Morphine is a substrate of the organic cation transporter OCT1 and polymorphisms in OCT1 gene affect morphine pharmacokinetics after codeine administration. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23835420/),[cm] / [s],8.2 × 10⁻⁶,218869,DB00904,Ondansetron
,18648229,maximal DeltaDeltaQTcF,The combination of droperidol and ondansetron significantly increased the mean maximal DeltaDeltaQTcF by 28 +/- 10 ms.,Droperidol and ondansetron-induced QT interval prolongation: a clinical drug interaction study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18648229/),ms,28,219295,DB00904,Ondansetron
,15098801,relative bioavailability,"There were no significant differences in pharmacokinetic parameters between the two formulations, and the relative bioavailability of the capsule versus the solution formulation was 101%.",Relative bioavailability of an extemporaneous ondansetron 4-mg capsule formulation versus solution. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15098801/),%,101,224428,DB00904,Ondansetron
,32250181,bioadhesion force,"The gel formulation G5 showed the most suitable gelation temperature (31 °C), viscosity (1250 mpoise), bioadhesion force (5860 ± 28 dyne/cm2), and in vitro drug release (70.6%) after 12 h.",Formulation and evaluation of niosomal vesicles containing ondansetron HCL for trans-mucosal nasal drug delivery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32250181/),[dyne] / [cm2],5860,226574,DB00904,Ondansetron
,32250181,relative bioavailability,Comparative in vivo pharmacokinetic study on rabbits showed a sustained release and higher relative bioavailability of the prepared nasal in situ gel compared to similar dose of oral tablets (202.4%) which make ondansetron HCl niosomal nasal thermo-sensitive in situ gel a more convenient dosage form for the administration of ondansetron HCl than oral tablets.,Formulation and evaluation of niosomal vesicles containing ondansetron HCL for trans-mucosal nasal drug delivery. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32250181/),%,202.4,226575,DB00904,Ondansetron
,25131428,peak plasma concentration (Cmax ),The peak plasma concentration (Cmax ) was 11.5 ± 10.0 ng/mL at 1.1 ± 0.8 h.,Pharmacokinetic modeling and Monte Carlo simulation of ondansetron following oral administration in dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25131428/),[ng] / [ml],11.5,230949,DB00904,Ondansetron
,25131428,area under the plasma concentration vs. time curve from time zero to the last measurable concentration,"The area under the plasma concentration vs. time curve from time zero to the last measurable concentration was 15.9 ± 14.7 ng·h/mL, and the half-life calculated from the terminal phase was 1.3 ± 0.7 h.",Pharmacokinetic modeling and Monte Carlo simulation of ondansetron following oral administration in dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25131428/),[h·ng] / [ml],15.9,230950,DB00904,Ondansetron
,25131428,half-life,"The area under the plasma concentration vs. time curve from time zero to the last measurable concentration was 15.9 ± 14.7 ng·h/mL, and the half-life calculated from the terminal phase was 1.3 ± 0.7 h.",Pharmacokinetic modeling and Monte Carlo simulation of ondansetron following oral administration in dogs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25131428/),h,1.3,230951,DB00904,Ondansetron
,21713460,Absolute bioavailability,Absolute bioavailability of the transdermal film studied was estimated to be 0.37 ± 0.06 which is quite low because a very high drug loading in the transdermal system was essential to achieve sufficient thermodynamic activity for transdermal permeation.,Preclinical evaluation of drug in adhesive type ondansetron loaded transdermal therapeutic systems. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21713460/),,0.37,233259,DB00904,Ondansetron
,32495990,CSF to plasma partition coefficients,The individual model-estimated CSF to plasma partition coefficients of ondansetron were between 0.09 and 0.20.,Plasma and cerebrospinal fluid pharmacokinetics of ondansetron in humans. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32495990/),,0.09 and 0.20,236701,DB00904,Ondansetron
,32495990,CSF penetration ratios,"These values were mirrored in the calculated CSF penetration ratios, ranging from 0.08 to 0.26.",Plasma and cerebrospinal fluid pharmacokinetics of ondansetron in humans. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32495990/),,0.08 to 0.26,236702,DB00904,Ondansetron
,1688516,major response rate (CR + MR),The major response rate (CR + MR) was thus 35%.,A phase I/II study of the 5-HT3 antagonist GR38032F in the anti-emetic prophylaxis of patients receiving high-dose cisplatin chemotherapy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1688516/),%,35,250050,DB00904,Ondansetron
,9788577,AUCs,"Median AUCs of cyclophosphamide in patients receiving ondansetron (73.6 mg/ml x min) were lower than those of the control patients (88.3 mg/ml x min, n = 75, P = 0.0004), but the median cisplatin AUC was approximately 10% higher and no difference in the disposition of carmustine was demonstrated.",Pharmacokinetic interaction between ondansetron and cyclophosphamide during high-dose chemotherapy for breast cancer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9788577/),[mg] / [min·ml],73.6,256672,DB00904,Ondansetron
,9788577,AUCs,"Median AUCs of cyclophosphamide in patients receiving ondansetron (73.6 mg/ml x min) were lower than those of the control patients (88.3 mg/ml x min, n = 75, P = 0.0004), but the median cisplatin AUC was approximately 10% higher and no difference in the disposition of carmustine was demonstrated.",Pharmacokinetic interaction between ondansetron and cyclophosphamide during high-dose chemotherapy for breast cancer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9788577/),[mg] / [min·ml],88.3,256673,DB00904,Ondansetron
,8893037,Km's,Slices gave consistently higher Km's (20 and 30 microM for hydroxylation and demethylation respectively) than hepatocytes (3 and 13 microM respectively) and microsomes (2 and 5 microM respectively.),"Metabolite kinetics of ondansetron in rat. Comparison of hepatic microsomes, isolated hepatocytes and liver slices, with in vivo disposition. ",Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8893037/),μM,20,261373,DB00904,Ondansetron
,8893037,Km's,Slices gave consistently higher Km's (20 and 30 microM for hydroxylation and demethylation respectively) than hepatocytes (3 and 13 microM respectively) and microsomes (2 and 5 microM respectively.),"Metabolite kinetics of ondansetron in rat. Comparison of hepatic microsomes, isolated hepatocytes and liver slices, with in vivo disposition. ",Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8893037/),μM,30,261374,DB00904,Ondansetron
,8893037,Km's,Slices gave consistently higher Km's (20 and 30 microM for hydroxylation and demethylation respectively) than hepatocytes (3 and 13 microM respectively) and microsomes (2 and 5 microM respectively.),"Metabolite kinetics of ondansetron in rat. Comparison of hepatic microsomes, isolated hepatocytes and liver slices, with in vivo disposition. ",Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8893037/),μM,3,261375,DB00904,Ondansetron
,8893037,Km's,Slices gave consistently higher Km's (20 and 30 microM for hydroxylation and demethylation respectively) than hepatocytes (3 and 13 microM respectively) and microsomes (2 and 5 microM respectively.),"Metabolite kinetics of ondansetron in rat. Comparison of hepatic microsomes, isolated hepatocytes and liver slices, with in vivo disposition. ",Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8893037/),μM,13,261376,DB00904,Ondansetron
,8893037,Km's,Slices gave consistently higher Km's (20 and 30 microM for hydroxylation and demethylation respectively) than hepatocytes (3 and 13 microM respectively) and microsomes (2 and 5 microM respectively.),"Metabolite kinetics of ondansetron in rat. Comparison of hepatic microsomes, isolated hepatocytes and liver slices, with in vivo disposition. ",Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8893037/),μM,2,261377,DB00904,Ondansetron
,8893037,Km's,Slices gave consistently higher Km's (20 and 30 microM for hydroxylation and demethylation respectively) than hepatocytes (3 and 13 microM respectively) and microsomes (2 and 5 microM respectively.),"Metabolite kinetics of ondansetron in rat. Comparison of hepatic microsomes, isolated hepatocytes and liver slices, with in vivo disposition. ",Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8893037/),μM,5,261378,DB00904,Ondansetron
,8893037,CL(int),"3. The high CL(int) of ondansetron (150 ml/min/SRW, where SRW is a standard rat weight of 250g) is well predicted by scaling either microsomal clearance for microsomal protein recovery or hepatocyte clearance for hepatocellularity (212 and 135 ml/min/SRW respectively).","Metabolite kinetics of ondansetron in rat. Comparison of hepatic microsomes, isolated hepatocytes and liver slices, with in vivo disposition. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8893037/),[ml] / [min·srw],150,261379,DB00904,Ondansetron
,8893037,CL(int),"3. The high CL(int) of ondansetron (150 ml/min/SRW, where SRW is a standard rat weight of 250g) is well predicted by scaling either microsomal clearance for microsomal protein recovery or hepatocyte clearance for hepatocellularity (212 and 135 ml/min/SRW respectively).","Metabolite kinetics of ondansetron in rat. Comparison of hepatic microsomes, isolated hepatocytes and liver slices, with in vivo disposition. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8893037/),[ml] / [min·sr],212,261380,DB00904,Ondansetron
,8893037,CL(int),"3. The high CL(int) of ondansetron (150 ml/min/SRW, where SRW is a standard rat weight of 250g) is well predicted by scaling either microsomal clearance for microsomal protein recovery or hepatocyte clearance for hepatocellularity (212 and 135 ml/min/SRW respectively).","Metabolite kinetics of ondansetron in rat. Comparison of hepatic microsomes, isolated hepatocytes and liver slices, with in vivo disposition. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8893037/),[ml] / [min·sr],135,261381,DB00904,Ondansetron
,8893037,CL(int),"In contrast, the use of liver slice data scaled to a whole liver substantially underestimates CL(int) (9 ml/min/SRW).","Metabolite kinetics of ondansetron in rat. Comparison of hepatic microsomes, isolated hepatocytes and liver slices, with in vivo disposition. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8893037/),[ml] / [min·srw],9,261382,DB00904,Ondansetron
,8485026,plasma clearance,"In comparison with the healthy controls, the patients with severe hepatic impairment had a lower mean plasma clearance (96 ml min-1 vs 478 ml min-1) and increased AUC (1383 ng ml-1 h vs 279 ng ml-1 h) and t1/2 (21 h vs 3.6 h).",The pharmacokinetics of intravenous ondansetron in patients with hepatic impairment. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8485026/),[ml] / [min],96,262019,DB00904,Ondansetron
,8485026,plasma clearance,"In comparison with the healthy controls, the patients with severe hepatic impairment had a lower mean plasma clearance (96 ml min-1 vs 478 ml min-1) and increased AUC (1383 ng ml-1 h vs 279 ng ml-1 h) and t1/2 (21 h vs 3.6 h).",The pharmacokinetics of intravenous ondansetron in patients with hepatic impairment. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8485026/),[ml] / [min],478,262020,DB00904,Ondansetron
,8485026,AUC,"In comparison with the healthy controls, the patients with severe hepatic impairment had a lower mean plasma clearance (96 ml min-1 vs 478 ml min-1) and increased AUC (1383 ng ml-1 h vs 279 ng ml-1 h) and t1/2 (21 h vs 3.6 h).",The pharmacokinetics of intravenous ondansetron in patients with hepatic impairment. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8485026/),[h·ng] / [ml],1383,262021,DB00904,Ondansetron
,8485026,AUC,"In comparison with the healthy controls, the patients with severe hepatic impairment had a lower mean plasma clearance (96 ml min-1 vs 478 ml min-1) and increased AUC (1383 ng ml-1 h vs 279 ng ml-1 h) and t1/2 (21 h vs 3.6 h).",The pharmacokinetics of intravenous ondansetron in patients with hepatic impairment. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8485026/),[h·ng] / [ml],279,262022,DB00904,Ondansetron
,8485026,t1/2,"In comparison with the healthy controls, the patients with severe hepatic impairment had a lower mean plasma clearance (96 ml min-1 vs 478 ml min-1) and increased AUC (1383 ng ml-1 h vs 279 ng ml-1 h) and t1/2 (21 h vs 3.6 h).",The pharmacokinetics of intravenous ondansetron in patients with hepatic impairment. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8485026/),h,21,262023,DB00904,Ondansetron
,8485026,t1/2,"In comparison with the healthy controls, the patients with severe hepatic impairment had a lower mean plasma clearance (96 ml min-1 vs 478 ml min-1) and increased AUC (1383 ng ml-1 h vs 279 ng ml-1 h) and t1/2 (21 h vs 3.6 h).",The pharmacokinetics of intravenous ondansetron in patients with hepatic impairment. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8485026/),h,3.6,262024,DB00904,Ondansetron
less,2533904,oral systemic bioavailability,"In laboratory animals absorption of the compound across the gastrointestinal tract is rapid and extensive, but due to high first-pass metabolism, the oral systemic bioavailability is low (less than 10%).",The metabolism of ondansetron. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2533904/),%,10,265394,DB00904,Ondansetron
more,22645289,extraction recoveries,"The extraction recoveries obtained from the SIPSE method were all more than 96% for dolasetron, hydrodolasetron and ondansetron (internal standard).",Optimization of sample pretreatment methods for simultaneous determination of dolasetron and hydrodolasetron in human plasma by HPLC-ESI-MS. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22645289/),%,96,266619,DB00904,Ondansetron
,12867217,AUC(0- infinity ),"Coadministration of aprepitant 375 mg produced a small but statistically significant increase in the AUC(0- infinity ) for intravenous ondansetron (from 1268.3 to 1456.5 ng.h/mL; P = 0.019), with no significant effect on peak concentration at the end of the infusion (360.8 ng/mL with aprepitant vs 408.4 ng/mL without) or t(12) (5.0 vs 4.5 hours, respectively).",Effects of aprepitant on the pharmacokinetics of ondansetron and granisetron in healthy subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12867217/),[h·ng] / [ml],1268.3,267183,DB00904,Ondansetron
,12867217,AUC(0- infinity ),"Coadministration of aprepitant 375 mg produced a small but statistically significant increase in the AUC(0- infinity ) for intravenous ondansetron (from 1268.3 to 1456.5 ng.h/mL; P = 0.019), with no significant effect on peak concentration at the end of the infusion (360.8 ng/mL with aprepitant vs 408.4 ng/mL without) or t(12) (5.0 vs 4.5 hours, respectively).",Effects of aprepitant on the pharmacokinetics of ondansetron and granisetron in healthy subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12867217/),[h·ng] / [ml],1456.5,267184,DB00904,Ondansetron
,12867217,peak concentration,"Coadministration of aprepitant 375 mg produced a small but statistically significant increase in the AUC(0- infinity ) for intravenous ondansetron (from 1268.3 to 1456.5 ng.h/mL; P = 0.019), with no significant effect on peak concentration at the end of the infusion (360.8 ng/mL with aprepitant vs 408.4 ng/mL without) or t(12) (5.0 vs 4.5 hours, respectively).",Effects of aprepitant on the pharmacokinetics of ondansetron and granisetron in healthy subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12867217/),[ng] / [ml],360.8,267185,DB00904,Ondansetron
,12867217,peak concentration,"Coadministration of aprepitant 375 mg produced a small but statistically significant increase in the AUC(0- infinity ) for intravenous ondansetron (from 1268.3 to 1456.5 ng.h/mL; P = 0.019), with no significant effect on peak concentration at the end of the infusion (360.8 ng/mL with aprepitant vs 408.4 ng/mL without) or t(12) (5.0 vs 4.5 hours, respectively).",Effects of aprepitant on the pharmacokinetics of ondansetron and granisetron in healthy subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12867217/),[ng] / [ml],408.4,267186,DB00904,Ondansetron
,12867217,t(12),"Coadministration of aprepitant 375 mg produced a small but statistically significant increase in the AUC(0- infinity ) for intravenous ondansetron (from 1268.3 to 1456.5 ng.h/mL; P = 0.019), with no significant effect on peak concentration at the end of the infusion (360.8 ng/mL with aprepitant vs 408.4 ng/mL without) or t(12) (5.0 vs 4.5 hours, respectively).",Effects of aprepitant on the pharmacokinetics of ondansetron and granisetron in healthy subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12867217/),h,5.0,267187,DB00904,Ondansetron
,12867217,t(12),"Coadministration of aprepitant 375 mg produced a small but statistically significant increase in the AUC(0- infinity ) for intravenous ondansetron (from 1268.3 to 1456.5 ng.h/mL; P = 0.019), with no significant effect on peak concentration at the end of the infusion (360.8 ng/mL with aprepitant vs 408.4 ng/mL without) or t(12) (5.0 vs 4.5 hours, respectively).",Effects of aprepitant on the pharmacokinetics of ondansetron and granisetron in healthy subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12867217/),h,4.5,267188,DB00904,Ondansetron
,12867217,AUC(0- infinity ),"Coadministration of aprepitant 125 mg/80 mg did not alter the mean pharmacokinetic characteristics of oral granisetron (AUC(0- infinity ), 101.4 ng.h/mL with aprepitant vs 92.2 ng.h/mL without; maximum plasma concentration, 9.0 ng/mL with and without aprepitant; time to maximum plasma concentration, both 3.0 hours; t(12), 6.5 vs 6.9 hours, respectively).",Effects of aprepitant on the pharmacokinetics of ondansetron and granisetron in healthy subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12867217/),[h·ng] / [ml],101.4,267189,DB00904,Ondansetron
,12867217,AUC(0- infinity ),"Coadministration of aprepitant 125 mg/80 mg did not alter the mean pharmacokinetic characteristics of oral granisetron (AUC(0- infinity ), 101.4 ng.h/mL with aprepitant vs 92.2 ng.h/mL without; maximum plasma concentration, 9.0 ng/mL with and without aprepitant; time to maximum plasma concentration, both 3.0 hours; t(12), 6.5 vs 6.9 hours, respectively).",Effects of aprepitant on the pharmacokinetics of ondansetron and granisetron in healthy subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12867217/),[h·ng] / [ml],92.2,267190,DB00904,Ondansetron
,12867217,maximum plasma concentration,"Coadministration of aprepitant 125 mg/80 mg did not alter the mean pharmacokinetic characteristics of oral granisetron (AUC(0- infinity ), 101.4 ng.h/mL with aprepitant vs 92.2 ng.h/mL without; maximum plasma concentration, 9.0 ng/mL with and without aprepitant; time to maximum plasma concentration, both 3.0 hours; t(12), 6.5 vs 6.9 hours, respectively).",Effects of aprepitant on the pharmacokinetics of ondansetron and granisetron in healthy subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12867217/),[ng] / [ml],9.0,267191,DB00904,Ondansetron
,12867217,time to maximum plasma concentration,"Coadministration of aprepitant 125 mg/80 mg did not alter the mean pharmacokinetic characteristics of oral granisetron (AUC(0- infinity ), 101.4 ng.h/mL with aprepitant vs 92.2 ng.h/mL without; maximum plasma concentration, 9.0 ng/mL with and without aprepitant; time to maximum plasma concentration, both 3.0 hours; t(12), 6.5 vs 6.9 hours, respectively).",Effects of aprepitant on the pharmacokinetics of ondansetron and granisetron in healthy subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12867217/),h,3.0,267192,DB00904,Ondansetron
,12867217,t(12),"Coadministration of aprepitant 125 mg/80 mg did not alter the mean pharmacokinetic characteristics of oral granisetron (AUC(0- infinity ), 101.4 ng.h/mL with aprepitant vs 92.2 ng.h/mL without; maximum plasma concentration, 9.0 ng/mL with and without aprepitant; time to maximum plasma concentration, both 3.0 hours; t(12), 6.5 vs 6.9 hours, respectively).",Effects of aprepitant on the pharmacokinetics of ondansetron and granisetron in healthy subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12867217/),h,6.5,267193,DB00904,Ondansetron
,12867217,t(12),"Coadministration of aprepitant 125 mg/80 mg did not alter the mean pharmacokinetic characteristics of oral granisetron (AUC(0- infinity ), 101.4 ng.h/mL with aprepitant vs 92.2 ng.h/mL without; maximum plasma concentration, 9.0 ng/mL with and without aprepitant; time to maximum plasma concentration, both 3.0 hours; t(12), 6.5 vs 6.9 hours, respectively).",Effects of aprepitant on the pharmacokinetics of ondansetron and granisetron in healthy subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12867217/),h,6.9,267194,DB00904,Ondansetron
,23053255,T (max),Twelve patients completed the study; T (max) occurred approximately 2 h after the initiation of the infusion.,Effect of aprepitant on the pharmacokinetics of the cyclin-dependent kinase inhibitor dinaciclib in patients with advanced malignancies. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23053255/),h,2,272846,DB00904,Ondansetron
,10223773,peak plasma concentration,Rifampin decreased the peak plasma concentration of oral ondansetron by about 50% (from 27.2+/-3.0 to 13.8+/-1.5 ng/mL [mean +/- SEM]; P < .001]) and the elimination half-life (t1/2) by 38% (P < .01).,The effect of rifampin on the pharmacokinetics of oral and intravenous ondansetron. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10223773/),[ng] / [ml],27.2,273326,DB00904,Ondansetron
,10223773,peak plasma concentration,Rifampin decreased the peak plasma concentration of oral ondansetron by about 50% (from 27.2+/-3.0 to 13.8+/-1.5 ng/mL [mean +/- SEM]; P < .001]) and the elimination half-life (t1/2) by 38% (P < .01).,The effect of rifampin on the pharmacokinetics of oral and intravenous ondansetron. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10223773/),[ng] / [ml],13.8,273327,DB00904,Ondansetron
,10223773,bioavailability,The bioavailability of oral ondansetron was reduced from 60% to 40% (P < .01) by rifampin.,The effect of rifampin on the pharmacokinetics of oral and intravenous ondansetron. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10223773/),%,60,273328,DB00904,Ondansetron
,10223773,bioavailability,The bioavailability of oral ondansetron was reduced from 60% to 40% (P < .01) by rifampin.,The effect of rifampin on the pharmacokinetics of oral and intravenous ondansetron. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10223773/),%,40,273329,DB00904,Ondansetron
,10223773,clearance,The clearance of intravenous ondansetron was increased 83% (from 440+/-38.4 to 805+/-44.6 mL/min [P < .001]) by rifampin.,The effect of rifampin on the pharmacokinetics of oral and intravenous ondansetron. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10223773/),[ml] / [min],440,273330,DB00904,Ondansetron
,10223773,clearance,The clearance of intravenous ondansetron was increased 83% (from 440+/-38.4 to 805+/-44.6 mL/min [P < .001]) by rifampin.,The effect of rifampin on the pharmacokinetics of oral and intravenous ondansetron. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10223773/),[ml] / [min],805,273331,DB00904,Ondansetron
,26966895,flow rate,"Chromatographic separation was performed on a Waters BEH C18 column with an isocratic elution using a mobile phase composed of acetonitrile and water, each with 0.1% formic acid, (80: 20, v/v), at a flow rate of 0.2 mL/min.",Simultaneous determination of selected tyrosine kinase inhibitors with corticosteroids and antiemetics in rat plasma by solid phase extraction and ultra-performance liquid chromatography-tandem mass spectrometry: Application to pharmacokinetic interaction studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26966895/),[ml] / [min],0.2,273626,DB00904,Ondansetron
,26966895,m/,"Quantitation of the analytes was performed using the multiple reaction monitoring (MRM) mode with the positive ionization mode at m/z 447.25>128.08 (GEF), m/z 394.20>278.04 (ERL), m/z 393.30>147.04 (DEX), m/z 361.29>147.02 (PRED), m/z 294.18>170.16 (OND), and m/z 426.26>175.07 (DOM).",Simultaneous determination of selected tyrosine kinase inhibitors with corticosteroids and antiemetics in rat plasma by solid phase extraction and ultra-performance liquid chromatography-tandem mass spectrometry: Application to pharmacokinetic interaction studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26966895/),,36,273627,DB00904,Ondansetron
,26966895,m/,"Quantitation of the analytes was performed using the multiple reaction monitoring (MRM) mode with the positive ionization mode at m/z 447.25>128.08 (GEF), m/z 394.20>278.04 (ERL), m/z 393.30>147.04 (DEX), m/z 361.29>147.02 (PRED), m/z 294.18>170.16 (OND), and m/z 426.26>175.07 (DOM).",Simultaneous determination of selected tyrosine kinase inhibitors with corticosteroids and antiemetics in rat plasma by solid phase extraction and ultra-performance liquid chromatography-tandem mass spectrometry: Application to pharmacokinetic interaction studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26966895/),,147.02,273628,DB00904,Ondansetron
,26966895,m/,"Quantitation of the analytes was performed using the multiple reaction monitoring (MRM) mode with the positive ionization mode at m/z 447.25>128.08 (GEF), m/z 394.20>278.04 (ERL), m/z 393.30>147.04 (DEX), m/z 361.29>147.02 (PRED), m/z 294.18>170.16 (OND), and m/z 426.26>175.07 (DOM).",Simultaneous determination of selected tyrosine kinase inhibitors with corticosteroids and antiemetics in rat plasma by solid phase extraction and ultra-performance liquid chromatography-tandem mass spectrometry: Application to pharmacokinetic interaction studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26966895/),,170.16,273629,DB00904,Ondansetron
,26966895,Er%,The method provided good extraction recovery of all analytes from rat plasma (Er% from -14.05 to -1.08).,Simultaneous determination of selected tyrosine kinase inhibitors with corticosteroids and antiemetics in rat plasma by solid phase extraction and ultra-performance liquid chromatography-tandem mass spectrometry: Application to pharmacokinetic interaction studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26966895/),,1,273630,DB00904,Ondansetron
